

**Synthesis, Characterization and Biological Activity Determination
of Silver Nanocubes**



MANAL BINT FAIZ

Registration # 00000318156

**Atta-ur-Rahman School of Applied Biosciences,
National University of Sciences and Technology,
Islamabad, Pakistan**

2022

Synthesis, Characterization and Biological Activity Determination of Silver Nanocubes

A thesis submitted in partial fulfillment of
the requirement for the degree of Master of Sciences

in

Healthcare Biotechnology

By

MANAL BINT FAIZ

Registration # 00000318156


Supervised by: Dr. Rumeza Hanif


Atta-ur-Rahman School of Applied Biosciences,
National University of Sciences and Technology,
Islamabad, Pakistan.


2022

THESIS ACCEPTANCE CERTIFICATE

It is certified that final copy of MS thesis written by Ms. Manal Bint Faiz (Registration No. NUST00000318156) of ASAB has been vetted by undersigned, found complete in all respects as per NUST statutes/regulations, is free of plagiarism, errors and mistakes and is accepted as partial fulfillment for award of MS degree. It is further certified that necessary amendments as pointed out by GEC members of the scholar have also been incorporated in the said thesis.

Signature:  **Dr. Rumza Hanif**
Associate Professor
Department of Biotechnology
School of Applied Sciences (ASAS)
Tangard
Date: 29-09-2022

Signature (HOD):  **Dr. Soha Hanif**
Tanvir Professor
Head of Department (HOD)
Department of Biotechnology
School of Applied Sciences (ASAS), NUST-Islamabad
Date: 13.10.22

Signature (Dean/Principal):  **Dr. Farhat Ishtiaq**
Dean
School of Applied Sciences (ASAS)
Tangard
Date: 19.10.22

DECLARATION


I, **Manal Bint Faiz** (Reg # **NUST00000318156**), declare that all work presented in this thesis is the result of my own work. Where information has been derived from other sources, I confirm that this has been mentioned in the thesis. The work herein was carried out while I was a Post Graduate student at Atta-ur-Rahman School of Applied Biosciences, NUST, under the supervision of **Dr. Rumeza Hanif**.

Manal Bint Faiz

CERTIFICATE FOR PLAGIARISM

It is to confirm that MS thesis entitled "**Synthesis, Characterization and Biological Activity Determination of Silver Nanocubes**" of Ms. Manal Bint Faiz, Reg No. NUST00000318156, has been examined by me. I undertake that:

- 1 The thesis has significant new work/knowledge as compared to already published data elsewhere. No sentence, table, equation, diagram, paragraph or section has been copied verbatim from previous work except when placed under quotation marks and duly referenced.
- 2 The work presented is original and own work of the author i.e., there is no plagiarism. No idea, results or words of others have been presented as author's own work.
- 3 There is no fabrication of data or results such that the research is not accurately represented in the records. The thesis has been checked using Turnitin (a copy of the originality report attached and found within the limits as per HEC plagiarism policy and instruction issued from time to time.


DR. RUMEZA HANIF
Associate Professor
Department of Healthcare Biotechnology
Faculty of Applied
Biosciences, ASAB, NUST, Islamabad

Dr. Rumeza Hanif

(Supervisor)

Associate Professor

Healthcare Biotechnology

ASAB, NUST

Dedicated to my father, whose tremendous support and cooperation led me to this wonderful accomplishment

Manal Bint Faiz

ABSTRACT

Nanoparticles have been termed as one of the most fascinating findings of science and technology and are finding useful application in almost every field of life. These tiny particles are completely unique from their bulk counter parts as their nanoscale size makes them a great choice for administration in everyday machinery, medical equipment and even in the human body. They have shown great promise in disease diagnosis and prognosis, as drug carriers, and in the treatment of various pathological disorders. Metallic nanoparticles offer an extra advantage of tunable surface plasmon resonance (SPR) which allows them to be targeted by a certain wavelength when inside the body, leaving the tissues undamaged and affecting only the nanoparticles. Silver nanoparticles are among the most widely used metallic nanoparticles in the field of medicine, but the inert antibacterial potentials are by far their greatest hallmark. The antimicrobial and other biological properties seem to be greatly affected by various physicochemical properties of the synthesized silver nanoparticles. Studies have shown that polyol synthesis method is efficient for synthesizing AgNPs of desired shapes and sizes. During the present study we have optimized synthesis of silver nanocubes (AgNCs) using the polyol method. The AgNPs thus synthesized were checked for the desired shape using Scanning Electron Microscopy (SEM). We then investigated antibacterial of the synthesized AgNCs thorough disc diffusion assay, antioxidant activity using FRAP and DPPH assay, hemolytic activity potential, anti-inflammatory activity, and biofilm inhibition potential of these cubical shaped silver nanoparticles through the corresponding biological activity assays. In order to determine the shelf-life of the synthesized AgNCs we also tested the effect of aging on the behavior of these nanoparticles. Our results show that, in general, the cubical AgNPs are less potent in most of these assays as compared to their opposing shapes mentioned in other studies. Our results also indicate that these nanoparticles deteriorate during storage at room temperature in about 6 months as the aged AgNCs did not exhibit any activity at any concentration tested in any assay.

Antibacterial activity of the synthesized AgNCs was determined using seven different bacterial strains viz., *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Bacillus subtilis*, *Bacillus pumilus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Bordetella bronchiseptica*. The freshly synthesized AgNC samples showed no antibacterial activity against 6 out of seven species of bacteria tested. *Bacillus subtilis* was the only strain that displayed sensitivity to the freshly synthesized AgNCs discs. Interestingly, these bacteria exhibit a better sensitivity at lower concentration of AgNCs rather than at higher concentration. This observation hints at some kind of uptake mechanism that becomes saturated at the higher concentrations. This hypothesis however needs to be further investigated through experimentation. The freshly prepared AgNC samples exhibited antioxidant activity that was directly proportional to their concentration used in the assay. We conclude that the shape of the NP helps to protect the antioxidant activity of the active ingredient i.e., Ag⁺ ion. Our results indicate that these AgNCs are safe for clinical usage as they possess no hemolytic activity and they possess significant anti-inflammatory activity. Our results indicate that the AgNCs possess great potential for use in medicine. Nonetheless there is great need for further experimentation to elucidate in detail exact mechanisms of the observed characteristics and validation of their beneficial properties over AgNPs in other shapes.

ACKNOWLEDGEMENTS

All praise and gratitude to Almighty Allah, who responds to my whims and woes, and has blessed me with the capabilities to carry out my work with far more ease and honesty. Peace be upon Prophet Muhammad (S.A.W) for showing us the path of righteousness.

I would like to express special thanks to my supervisor, Dr. Rumeza Hanif, for her guidance throughout my thesis. Her patience and understanding allowed me to reach her at any time of need, and joined with her mentorship, it has helped me come this far.

I would also like to pay special thanks to Dr. Farooq Warsi and Dr. Samina Ejaz, The Islamia University of Bahawalpur, for their tremendous support and cooperation. Without their help and accommodation, I wouldn't have been able to complete my thesis.

A special thank you to my research fellows, Fakharu-nisa, Muhammad Irfan, and Aleena Haqqi, for all their support and assistance.

I would like to thank my GEC members Dr. Maria Shabbir, Dr. Saira Justin, and my external examiner Dr. Fahim Amin from School of Natural Sciences (SNS), NUST for their insightful comments and encouragement, which incited me to widen my research from various dimensions. I am profusely thankful to my beloved parents who have been a source of unconditional love and support throughout my life, thanks to which I am able to stand here today with such an achievement.

Finally, I would like to express my gratitude to all the individuals who have rendered valuable assistance during my studies.

Manal bint Faiz

Table of Contents

#	Content	Page Number
	ABSTRACT	vii
	ACKNOWLEDGEMENTS	ix
	Table of Contents	x
	List of Figures	xii
	List of Tables	xiii
	Chapter 1	
1.	INTRODUCTION	1
1.1.	Nanoparticles	1
1.2.	Types of Nanoparticles	1
1.3.	Sources of Nanoparticles	4
1.4.	Methods for Nanoparticle Synthesis	6
1.4.1.	Physical Methods	6
1.4.2.	Chemical Methods	7
1.4.3.	Biological Methods	9
1.5.	Biomedical Applications of Nanoparticles	16
1.6.	Silver Nanocubes	16
1.6.1.	Applications of Silver NPs in Biomedical Sciences	17
1.6.1.1.	Antibacterial Agents	17
1.6.1.2.	Drug Delivery Systems	18
1.6.1.3.	Role in Cancer Treatments	19
1.6.1.4.	Biosensors and Bioimaging	20
	Chapter 2	23
2.	MATERIALS AND METHODS	23
2.1.	Silver Nanocube Synthesis	23
2.1.1.	Synthesis of Silver Nanocubes – Protocol 1	23
2.1.2.	Isolation of Nanocubes	24
2.1.3.	Synthesis of AgNCs – Protocol 2	24
2.1.4.	Isolation of Nanocubes	24

2.1.5. UV-Visible Spectroscopy	25
2.1.6. Characterization of the Nanocubes	25
2.2. Antibacterial Assay	25
2.3. Antioxidant Assays	26
2.3.1. FRAP Assay	26
2.3.2. DPPH Assay	28
2.4. Hemolytic Activity	29
2.5. Anti-inflammatory Activity	30
2.6. Biofilm Inhibition Assay using Microtiter-plate method	31
Chapter 3	33
3. RESULTS AND DISCUSSION	33
3.1. Synthesis of Nanoparticles	33
3.2. Activities of Synthesized Nanocubes	37
3.2.1. Antibacterial Activity	38
3.2.2. Antioxidant Activity	52
3.2.3. Hemolytic Activity	56
3.2.4. Anti-inflammatory Activity	57
3.2.5. Biofilm Activity	58
CONCLUSIONS	60
Plagiarism Report	61
REFERENCES	62

List of Figures

Figure No.	Figure Title	Page No.
Fig. 1	UV Reading of Synthesized AgNCs	34
Fig. 2	SEM of Synthesized AgNCs	35
Fig. 3	SEM of Synthesized AgNCs	36
Fig. 4	SEM of Synthesized AgNCs	36
Fig. 5	SEM of Synthesized AgNCs	37
Fig. 6	Evaluation of the Antibacterial Activity of the aged AgNCs	42
Fig. 7	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>P. aeruginosa</i>	43
Fig. 8	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. pumilus</i>	44
Fig. 9	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. bronchiseptica</i>	45
Fig. 10	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>S. aureus</i>	46
Fig. 11	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>E. coli</i>	47
Fig. 12	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>S. epidermidis</i>	48
Fig. 13	Evaluation of the antibacterial activity of freshly prepared AgNPs using 6 bacterial strains and discs carrying 30% and 1% nanoparticles solution	49
Fig. 14	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. subtilis</i>	50
Fig. 15	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. subtilis</i> and discs carrying 30% and 1% nanoparticles solution	51
Fig. 16	Evaluation of the antioxidant potential of the nanoparticles using FRAP assay	54

List of Figures

Figure No.	Figure Title	Page No.
Fig. 1	UV Reading of Synthesized AgNCs	34
Fig. 2	SEM of Synthesized AgNCs	35
Fig. 3	SEM of Synthesized AgNCs	36
Fig. 4	SEM of Synthesized AgNCs	36
Fig. 5	SEM of Synthesized AgNCs	37
Fig. 6	Evaluation of the Antibacterial Activity of the aged AgNCs	42
Fig. 7	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>P. aeruginosa</i>	43
Fig. 8	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. pumilus</i>	44
Fig. 9	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. bronchiseptica</i>	45
Fig. 10	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>S. aureus</i>	46
Fig. 11	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>E. coli</i>	47
Fig. 12	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>S. epidermidis</i>	48
Fig. 13	Evaluation of the antibacterial activity of freshly prepared AgNPs using 6 bacterial strains and discs carrying 30% and 1% nanoparticles solution	49
Fig. 14	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. subtilis</i>	50
Fig. 15	Evaluation of the antibacterial activity of the freshly synthesized AgNPs using <i>B. subtilis</i> and discs carrying 30% and 1% nanoparticles solution	51
Fig. 16	Evaluation of the antioxidant potential of the nanoparticles using FRAP assay	54

CHAPTER 1: INTRODUCTION

1.1 Nanoparticles

Nanoparticles (NPs) are a state of matter with properties unique from their molecular or bulk counter parts. NPs are ultrafine, microscopic material measured between 1 to 100 nm size range [1]. Matter manipulation at the nanoscale was first brought to light by Richard Feynman in 1960 where he highlighted the fact that atoms follow different laws of nature at the quantum level [2]. Nano-sized particles gained importance due to their unique and tunable properties. These unique properties at such miniature scale have been exploited in various fields of science including Physics, Chemistry and Biology. Once the customization of NPs became common practice, it was only a matter of time before these NPs established distinct roles in different fields of science. The manipulation of NPs is now widely termed as Nanotechnology.

1.2 Types of Nanoparticles:

An assortment of different NPs has been developed as per their use and composition. According to a general classification, these NPs fall into two major groups; organic and inorganic NPs [3]. The second classification i.e. the three-category system of organic, inorganic and carbon-based NPs is more recent and accepted worldwide [4].

This three-category classification of nanoparticles is briefly described below.

1. **Organic NPs:** This group includes
 - a. Dendrimers are unique polymeric nanostructures with a branched morphology [5].
 - b. Micelles are amphiphilic surfactant molecules and instinctively shift in aqueous environment. They primarily form a spherical vesicle with a hollow core [6]. These

types of NPs, for the most part, maintain a hydrophobic center which enables these cores to hold hydrophobic drugs and act as drug delivery vehicles [7].

- c. Liposomes [8] are structures much like micelles. They are composed of lipid bilayer that self-assembles in aqueous environment into a spherical form. This spherical vesicle confines liquid in the center which can be exploited in carrying drugs [9]
- d. Ferritin, a well-known iron storage protein, has been manipulated and utilized as NPs as a result of its distinctive architecture [10]. A ferritin molecule is composed of an outer and inner surface, both appropriate features for surface modification and drug loading, respectively.

These NPs are biodegradable, non-toxic, and are mostly excellent drug carriers owing to the presence of polymeric configuration and hollow cores in most of the structures.

2. **Carbon-based NPs:** As the name indicates, this category incorporates NPs made solely out of carbon. Nano sized carbon particles include;

- a. Fullerenes, also known as bucky balls, with a diameter of about 7 ampere. They are excellent for carrying DNA within their hollow structure. The most common configuration of fullerenes involves 60 carbon atoms arranged in a spherical structure [11].
- b. Carbon nanotubes are carbon-based tubular structures formed by a graphite sheet rolled up into a cylinder. These tubes are hexagonal arrangements of carbon atoms in a helical manner, providing needle like hollow structures with diameters of around 1 nm and lengths ranging up to 100 nm [12]. Changing the size, thickness,

and hollow core structure of nanotubes has led to alternate versions of carbon nanotubes referred to as nanorods [13], nanowires [14], and nanofibers [15]

3. **Inorganic NPs:** This group of NPs can be further categorized into four nanosystems, namely metallic, bimetallic, magnetic and metal oxide NPs, for ease of understanding [16].
 - a. **Metallic NPs:** Nanosized entities made of pure metal build this subcategory of inorganic NPs. This class, for the most part, consists of Gold (Au) and Silver (Ag) NPs. Such NPs display electronic as well as optical properties that are sought after especially for diagnosis of cancer [17]. These properties along with their chemical inertness [18] and easily modifiable surfaces [19] make pure metallic NPs a very promising tool especially in the biomedical fields.
 - b. **Bimetallic NPs:** They can also be referred to as alloy NPs, include NPs such as Iron Cobalt (Fe-Co) [20], Iron Nickel (Fe-Ni) [21], Copper Nickel (Cu-Ni) [22], Iron Platinum (Fe-Pt) [23] to name a few. These NPs possess particularly attractive features for their use in hyperthermia treatment [24], MRI contrast agents [25], drug delivery [26], and Biosensors [27].
 - c. **Magnetic NPs:** Magnetic NPs generally depict the NPs that comprise of magnetite (Fe_3O_4) or maghemite ($\gamma\text{-Fe}_2\text{O}_3$) and are among the most commonly synthesized and utilized NP [28]. Iron Oxides exhibit remarkable chemical, biological and magnetic properties which make them popular candidates for biomedical applications [29].
 - d. **Metal Oxide NPs:** As the name indicates, these kinds of NPs encompass a large diversity of oxides that metal elements form. Titanium DiOxide (TiO_2) [30],

Cerium Oxide (CeO₂) [31], Mesoporous Silica NPs (SiO₂) [32], Zinc Oxide (ZnO) [33], and other metal oxides make up this group of inorganic NPs.

Metallic NPs have been of great interest as they show peculiar physiochemical properties in the nanometer size range. Their size, shape, pore size, surface charge and other characteristics can be modified according to one's interest. NPs synthesized from metal oxides such as Iron Oxide, Zinc Oxide and others are the examples. Metal oxide NPs are highly reactive and are used in the fabrication of their respective metal NPs.

Quantum Dots:

Another class of inorganic NPs are the Quantum Dots which are synthesized from elements in the classical semiconductor groups III-V and II-VI of the periodic table [34]. They predominantly comprise of a semiconductor inorganic core (CdSe) and an organic coated shell (e.g. ZnS) to improve their optical properties. Quantum dots have been observed to produce fluorescence when stimulated by light [35]. They have been successfully utilized in immunoassays [36, 37], DNA hybridization detection [38, 39], for cancer diagnosis and treatment [40], gene therapy [41] etc.

Hybrid NPs:

Dendrimer-encapsulated metal NPs are a form of organic/inorganic hybrid NPs. They are the result of a dendrimer coat with a metal ion core followed by subsequent chemical reduction [42].

1.3 Sources of Nanoparticles:

NPs can be generated from natural resources or they can be generated following a pure synthetic/chemical route. The advancement in the field of nanotechnology has created numerous possibilities for NP synthesis using a diverse collection of materials/mediums/substances.

Metallic or non-metallic NPs can be synthesized both biologically and/or chemically. Various enzymes and/or proteins are suspected to be involved in the bio-reduction and stabilization of metal NPs in different organisms [43]. This 'Green synthesis' or 'Biosynthesis' is being exploited to produce bio-compatible and water-soluble NPs through an eco-friendly course of action [44].

Microorganisms and plants have been used in the bio-synthesis of metal NPs as well, although the exact mechanism is still unclear [45]. Production of NPs using biological sources allows more reproducibility, is non-toxic, and gives high yield.

NPs also exist naturally in our environment. Naturally existing NPs originate incidentally through mechanical/vehicular discharge or can be a result of weather/climate/atmospheric/environmental change. Additionally, naturally occurring biological processes of numerous organisms yield a wide range of NPs. Chemically engineered NPs are a result of human involvement and desire to create the most efficient NPs or to study their extraordinary properties and to exploit their novel/unique features [46-51]. Based on their synthetic versatility NPs can be categorized as;

1. Incidental NPs

NPs can be acquired through the environment. Gases from volcanic eruptions, desert dust storms, and even cosmic dust contain a large amount of NPs that reside and interact with the major components of air i.e. nitrogen, oxygen etc. [52].

2. Engineered NPs

The working of engines, automobiles, airplanes and other machines results in combustion of fuel oil and coal etc. All these and other anthropogenic factors lead to the formation of different and mostly toxic NPs released into the environment. Engineered NPs include those produced by automobiles, different machinery,

cigarettes and even the NPs synthesized in laboratories for human use, such as NPs used in cosmetics or in the biomedical field.

3. Naturally Occurring NPs

Naturally occurring NPs may be confused with incidental NPs as they are both produced as a result of naturally occurring phenomena. But naturally occurring NPs are specifically those NPs that are produced by different living organisms from the simplest of micro-organisms to the most complex multicellular life-forms.

1.4 Methods for Nanoparticle synthesis:

The intriguing properties that NPs possess are easily affected by their morphology, size, and basic material. The properties of NPs designed through the synthesis methods influence the application of said NPs. As such, a miscellany of methods has been generated that are used to synthesize the desired type of NP for a specific type of operation. These methods have been broadly classified into two major types, the top-down (destructive) and the bottom-up (constructive) approach [53]. NP synthesis, however, is preferably classified as Chemical, Physical or Biological methods [54].

1.4.1 Physical Methods

The most common physical methods for synthesis of NPs is the laser ablation method and the evaporation-condensation method which is also known as Inert-Gas Condensation (ICG).

The *Inert Gas Condensation* (IGC) method is a 'bottom-up' approach. It involves two major steps, evaporation of the source material and subsequent rapid and controlled condensation to form NPs. IGC allows synthesis of ultrafine NPs by controlling different parameters of the reaction such as evaporation temperature, inert gas pressure and others. Silver [55], Gold [56], Manganese [57], Magnesium [58], Copper [59], and a number of other metal NPs have been reported to be

synthesized via Inert Gas Condensation [60]. The major drawbacks of this method are the inaccessibility and high cost of the Inert Gas Chambers.

Another commonly used physical procedure is the *Laser Ablation* method. As the name states, this method involves the use of laser beam to break down large sample material into smaller NPs (Top-down approach) in a gaseous or liquid environment. For laser ablation in aqueous solutions a surfactant, generally Sodium Dodecyl Sulfate (SDS), is customarily used to prevent the NPs from forming clusters and help in uniform particle size generation. Gas phase laser ablation procedures make use of closed gas chambers for NP synthesis.

Laser ablation is an efficient means of producing monodispersed NPs as it eliminates the need for complex set-ups, high temperatures and toxic chemicals. This technique is considered time-saving and eco-friendly [61]. Silver NPs with controlled size can be generated using laser ablation method [62].

1.4.2 Chemical Methods

Chemical reduction is the most commonly used chemical synthesis method to produce metallic NPs. This process can be divided into three different phases using different reagents; a reducing agent which reduces the metallic salt; a stabilizing agent and a capping agent to prevent agglomeration to assure correct size distribution, respectively. As is evident in some protocols, a single chemical reagent may act as both reducing and stabilizing agent [63]. This method has indubitably been used countless times in the synthesis of silver NPs with a range of sizes and shapes such as nanospheres, nanowires, nanocubes, dendrites etc. [63-71]. Synthesis of metallic NPs such as Copper [72], Iron [73], Nickel [74], Gold [75], and others via chemical reduction method have been reported as well.

With the creation of colloidal nano-sized dispersions of water-in-oil (or vice versa) with a surfactant as stabilizer [76], the *microemulsion technique* offers great uniformity and size controllability of NPs formed. The nanodroplets formed act as nano-reactors in which the chemical reactions take place [77]. It follows a two-phase synthesis method based on interaction of metal precursor and reducing agent present in two immiscible liquids. Reports of Silver [78], Copper [79], Iron [80], Platinum [81], Cadmium, Zinc [82], Palladium [83], Nickel [84], and Gold [85] NPs via microemulsion method have been made. The major disadvantage of this method is the use of highly deleterious organic solvents.

Irradiation method comprises a predefined duration of laser radiation on a solution of metal precursor salt and surfactant. This produces metallic NPs of distinct size and shape. Silver NPs have been generated by γ -irradiation of AgNO_3 used as the precursor salt [86] and the size of NPs can be controlled by customizing the duration of radiation pulse applied on the sample [87].

Microwave assisted synthesis is a finer choice for heating than the conventional oil-bath heating method. It offers lower energy usage, reduced chemical waste, more efficient reaction, more precise size control and uniformity [88] [89]. Using this method, the shape of the NPs can be determined as well [90] [91].

UV-initiated photoreduction has also been implemented in NP synthesis. The size of the particles can be controlled by altering the duration of irradiation.

Photoinduced or photocatalytic reduction is considered a clean and cost-effective method for NP synthesis [92]. It is versatile, easy to use and has high spatial resolution. The shape and consequently the optical properties of the NPs can be modulated by the irradiation through light emitting diode [93]. NPs with size as small as 8 nm have been synthesized using this method [94].

NPs have also been successfully synthesized using *electrochemical synthetic method*. NPs are deposited at the interface of electrolyte solution containing precursor salt and a metal electrode substrate [95]. The size of NPs can be controlled by changing the electrolysis parameters while the overall size distribution is controlled by altering electrolyte solution composition [96] [97] .

Sonoelectrochemical technique combines sonic and electric pulses in the synthesis of NPs where size and shape formation are controlled by the electrolyte composition and ultrasound specifications. NPs produced through this method are predominately metallic in nature [98].

Several *polysaccharides and polymers* have also been employed in the synthesis of different types of NPs. In an environmentally friendly method, water is used as the solvent while a range of polysaccharides function as reducing and stabilizing agents [99]. For example, polymers with the capability of ion-exchange have been used in the synthesis of (silver) NPs.

Tollens' reagent test is a common test used to distinguish aldehydes and ketones. The main reagent in this procedure is silver diamine ($[\text{Ag}(\text{NH}_3)_2]^+$). This reagent has been exploited in the synthesis of silver NPs in the following method that uses polysaccharides/sugars as reducing agents for silver in the presence of ammonia [100]. In a modified green synthesis method, tollens reagent is used along with phytochemicals which act as the reducing agents [101]

1.4.3 Biological Methods

Although there are a range of physical and chemical methods to synthesize NPs of different shapes and sizes, some scientists argue that these methods make use of environmentally harmful and cost-ineffective chemicals. Thus, biological methods to synthesize NPs have been explored. In these methods living organisms are brought into play to synthesize NPs. Many of these organisms include bacteria, fungi, algae and a miscellany of plants.

The biological synthesis methods are considered more quick, cost-efficient, don't require high temperatures, and are less harmful than traditional physical and chemical methods [102]. These approaches are more similar to chemical synthesis methods in that they are bottom-up mechanisms that follow the oxidation/reduction of precursor salts. Various enzymes from microorganisms and plant phytochemicals act as antioxidant or reducing agents and encourage NP synthesis [103]. Exact mechanism for the biological synthesis of NPs is not entirely known at the moment but there is substantial *in silico* data that suggests the role of biomolecules as capping and/or reducing agents.

In the case of microorganisms, synthesis can occur extracellularly or intracellularly. During the extracellular process, cultures are grown under optimum conditions, centrifuged, and the biomass is removed. The supernatant of these cultures is then used along with precursor metal salt to synthesize NPs. The intracellular method is relatively similar. The major difference is that instead of removing the biomass, it is collected after centrifugation, washed, and then used to generate NPs by adding the precursor salt. For both these methods, the change in color of the sample is used as an indicator for NPs synthesis. In the intracellular synthesis method, an additional step to break the cell walls of the microorganisms to release and collect the NPs synthesized inside the cells needs to be carried out.

For synthesis via plants, plant extract (from different plant parts such as roots, bark, leaves) are used along with the precursor metal salt and water depending on the type of extract. Incubation of this reaction mixture leads to the reduction of metal salt and the change in color indicates the synthesis of the NPs [45]. Listed below are some microorganisms and plants reported to have been involved in the synthesis of various silver NPs.

The most diversely used microorganisms, *Bacteria*, as in other fields of life science, are largely used in the synthesis of numerous NPs as well. *Pseudomonas sp.*, for example, have been documented to synthesize AgNPs with an average size of 50 nm.

Table 1: NPs with varying sizes synthesized by bacterial and actinomycetes species.

Bacterial species	Nanoparticles	Size	Reference
<i>Pseudomonas sp.</i>	Ag	~50 nm	[104]
<i>Bacillus licheniformis</i>	Ag	40 nm	[105]
<i>Bacillus spp.</i>	Ag	77-92 nm	[106]
<i>Ochrobactrum anhtropi</i>	Ag	38-85 nm	[107]
<i>Pantoea ananatis</i>	Ag	8.06-91.32 nm	[108]
<i>Bacillus brevis</i> NCIM 2533	Ag	41–68 nm	[109]
<i>Bacillus mojavensis</i>	Ag	105 nm	[110]
BTCB15			
<i>Actinobacter</i>	Ag	13 nm	[111]
<i>Sinomonas mesophila</i>	Ag	4–50 nm	[112]
MPKL 26			
<i>Bacillus endophyticus</i>	Ag	5.1 nm	[113]
SCU-L			
<i>Bacillus licheniformis</i>	Ag	18.69–63.42 nm	[114]

Dahb1

<i>Bacillus methylotrophicus</i> DC3	Ag	10–30 nm	[115]
<i>Stenotrophomonas</i> GSG2	Ag and Au	Au (10–50); Ag (40–60)	[116]
<i>Bacillus subtilis</i>	Au	20–25 nm	[117]
<i>Shewanella loihica</i>	Au	2–15 nm	[118]
<i>Kocuria flava</i>	Cu	5–30 nm	[119]
<i>Shewanella loihica</i>	Cu	10–16 nm	[120]
<i>Shewanella loihica</i>	Pt	1–10 nm	[118]
<i>Shewanella loihica</i>	Pd	1–12 nm	[118]
<i>Staphylococcus aureus</i>	ZnO	10–50 nm	[121]
<i>Lactobacillus sp.</i>	TiO ₂	8–35 nm	[122]
Actinomycetes			
<i>Streptomyces spp.</i>	Ag	11–63 nm	[123]
<i>Nocardiopsis sp.</i> MBRC-1	Ag	45 nm	[124]
<i>Streptacidiphilus durhamensis</i>	Ag	8–48 nm	[125]
<i>Streptomyces rochei</i> MHM13	Ag	22–85 nm	[126]
<i>Streptomyces sp.</i>	Ag	15–25 nm	[127]

<i>Gordonia amicalis</i> <i>HS-11</i>	Au-Ag	5–25 nm	[128]
<i>Rhodococcus sp.</i>	Au	5–15 nm	[129]
<i>Nocardiopsis sp.</i> <i>MBRC-48</i>	Au	11.57 nm	[130]
<i>Streptomyces capillispiralis</i> <i>Ca-1</i>	Cu	3.6–59 nm	[131]
<i>Streptomyces sp.</i>	CuO	78–80 nm	[132]
<i>Streptomyces sp.</i>	ZnO	20–50	[133]

Fungal strains have also been reported to have a significant role in the shape of NPs synthesized [134]. They excrete proteins and enzymes in large quantities that help in reduction of metal salt and provide a process that can be easily scaled-up [135]. These and other qualities of fungal sp. have convinced scientists in using them for the production of NPs. Listed below are some fungal and yeast strains that have been used in the successful synthesis of NPs.

Table 2: Different types of NPs synthesized by fungal and yeast species.

Fungal Species	Nanoparticles	Size	Reference
<i>Rhizopus stolonifer</i>	Ag	2.86 nm	[136]
<i>Candida glabrata</i>	Ag	2–15 nm	[137]
<i>Trametes trogii</i>	Ag	5–65 nm	[138]
<i>Trichoderma longibrachiatum</i>	Ag	10 nm	[139]

<i>Fusarium oxysporum</i>	Ag	21.3 to 37.3 nm	[140]
<i>Aspergillus terreus</i>	Ag	16-57 nm	[141]
<i>Cladosporium</i> <i>cladosporioides</i>	Au	60 nm	[142]
<i>Rhizopus oryzae</i>	Au	16–43 nm	[143]
<i>Saccharomyces</i> <i>cerevisiae</i>	Au	-	[144]
<i>Penicillium</i> <i>chrysogenum</i>	Pt	5–40 nm	[145]
<i>Aspergillus niger</i>	ZnO	53–69 nm	[146]
<i>Pichia kudriavzevii</i>	ZnO	10–61 nm	[147]
<i>Alternaria alternata</i>	Fe ₂ O ₃	75–650 nm	[148]
<i>Saccharomyces</i>	Pd	32 nm	[149]

cerevisiae

The eukaryotic, aquatic, photoautotrophic organisms, *algae*, have been known to be capable of bioremediation by accumulating heavy metals from the surrounding environment. However, not many accounts of NP synthesis using algae have been reported. Red algae *Portieria hornemannii* [150], marine macroalgae *Padina* sp. [151], and *Gelidium amansii* [152] are a select few among a number of other algae that have successfully been used in the synthesis of AgNPs.

Another fascinating method reported for the synthesis of NPs is through the use of *viruses*. These nanoscale sized organisms are sought after because of their small yet controlled sizes and

morphologies. The unique chemistry of the viral capsid allows for its chemical modification and exploitation in generating NPs [153].

The first report of NPs synthesized by *plant* extract was made in 2003 through which silver NPs synthesis was documented using alfalfa sprouts [154]. Since then a countless number of plant species have been investigated and explored for the synthesis of NPs. Plant extracts have been known to contain certain phytochemicals that act as reducing and stabilizing agents which are key elements in the synthesis of NPs [155]. Till present, a great deal of plants has been used in the synthesis of all sorts of NPs, a few of which are mentioned below.

Table 3: List representing sizes and different NPs synthesized by plant species.

Plant Species	Nanoparticle	Size	Reference
<i>Annona reticulata</i>	Ag	7–8	[156]
<i>Camellia sinensis</i>	Ag	2–4	[157]
Mulberry fruit (<i>Morus alba</i> L.)	Ag	80–150	[158]
<i>Panax ginseng</i>	Ag	5–15	[159]
<i>Nigella arvensis</i>	Au	3–37	[160]
<i>Rhazya stricta</i> Decne	Au	40	[161]
Mulberry fruit (<i>Morus alba</i> L.)	Cu	50-200	[158]
(<i>Syzygium aromaticum</i>) clove	Cu	~ 15–20	[162]
<i>Moringa oleifera</i>	Fe	2.6–6.2	[163]

<i>Avicennia marina</i>	FeO	10–25	[164]
<i>Aloe socotrina</i>	ZnO	15–50	[165]

1.5 Biomedical Applications of Nanoparticles:

The specific properties of an element are contributed by the subatomic particle, the electrons. In metals especially, these electrons are greatly delocalized [166], having an average free path of about 10 to 100 nm. Therefore, in such elements, changes in size and shape are cause for substantial deviations in properties from their bulkier analogues, and new size-dependent properties emerge.

Owing to the extraordinary chemical and physical properties that NPs possess, there is no doubt that they would be extensively and ever so thoroughly exploited in the field of biomedicine. Their increased surface-to-volume ratio, easily modifiable surfaces, magnetic and optical properties make them superior to their larger counterparts especially in the diagnosis and therapy of diseases. In vitro trials of NPs in Drug Delivery [167], Bioimaging [168, 169], Biosensors [170], Photothermal Ablation [171], Hyperthermia [172], as Labelling and Tracking Agents [173], Gene Therapy [174] and others have been no less than positive.

One of the most intriguing and significant feature these NPs put forward is their adjustable and chemically modifiable surface. This remarkable trait to biofunctionalize NPs makes them biocompatible, easy for targeting and tracking inside the body, and less harmful for use [175].

1.6 Silver NanoCubes:

Silver nanoparticles (AgNPs) can be synthesized in specific shapes, each with their own unique properties such as nanospheres [176], nanorods, nanowires [177], nanoprisms [178], nanoshells [179], and nanocubes [180]. Depending on the size and shape of the AgNPs, their Surface Plasmon Resonance (SPR) and hence other optical properties, such as refraction, absorption, reflection and scattering of light, are altered [181]. The properties of AgNPs greatly depend on their shape and size. As the production of silver nanostructures exponentially grow it constitutes rapid growth in research in the field of nanomaterials.

Studies to control the shape of AgNPs to produce cubic structures have resulted in the formation of Silver Nanocubes (AgNCs) [182]. AgNCs have been pursued for their Surface Plasmons properties [183] and their optical properties [184].

AgNCs are generally prepared at high temperatures using a bottom-up chemical reduction method commonly referred to as the polyol synthesis [185]. Alterations in different parameters of the reaction, such as the chemicals [186], temperature [187], reaction time etc. [188], result in nanocubes of different sizes and also determine whether they will have sharp edges or curved corners. Silver mirror reaction is another approach that has successfully been used to synthesize AgNCs [189].

1.6.1 Applications (of silver NPs) in Biomedical Sciences:

Since the evolution of nanotechnology, AgNPs have become one of the most extensively researched and explored nanomaterials synthesized in view of the fact that these metal nanostructures provide unique, challenging, and promising properties desirable for various biomedical applications.

1.6.1.1 Antibacterial Agents:

Perhaps the most commonly conducted biomedical application of AgNPs are the *antibiotic assays* conducted due to their well-known intrinsic antimicrobial effect [190]. As a consequence of their antibacterial quality, they have been implemented in tissue scaffolds, protective clothing and wound dressing [191]. In context to this property, AgNPs incorporated in nanofibers have shown positive results against both gram positive and gram negative bacteria [192]. Studies indicate that storage and shelf life of AgNPs can be altered by modifying their surfaces. These studies have also shown that the AgNPs “age” over time during storage thus effecting their toxicity [193].

Various factors affect the antibacterial effect possessed by the AgNPs. For example, smaller sized NPs display greater antibacterial toxicity [194]. Similarly, shape of the NPs [195], concentration and the method selected to test antibacterial effect [196] and surface modifications [197] affect the antibacterial property of the NPs. Method of synthesis also affects the toxicity of AgNPs. Chemically synthesized AgNPs have been reported to show greater cytotoxic effect in comparison with green synthesized AgNPs [198].

It is worth mentioning that AgNPs when used in human cells cause cytotoxicity, genotoxicity [199], and inflammatory responses [200] in a cell-type-dependent manner. AgNPs have also been seen to have a positive role in wound healing in animal models [201].

There is an ongoing debate between scientists where some state that the AgNPs themselves show antibacterial effects while others believe the NPs release silver ions that go on to kill the bacteria. Despite the uncertainty of the exact process that takes place, studies have shown that silver ions are more potent killers of bacteria than the whole AgNP, and support the possible release of silver ions from AgNPs [202].

The intrinsic antibacterial property that AgNPs possess has widely and extensively been applied in various medical specializations/sectors including catheter modifications [203, 204] where AgNPs are combined with the catheter and promise a maintained sterilization effect, in dentistry [205], wound healing applications [206], infected bone repair [207] and more.

1.6.1.2 Drug Delivery Systems:

Understanding the Pharmacokinetics and Pharmacodynamics of drugs has always been a very crucial part of medicine. Following the target specific and selective action of drugs in the body and the advances in the field of nanotechnology, NPs have since been extensively studied regarding their novel design and development for their role as drug carriers as metallic NPs [208], polysaccharide-based NPs [209], Solid Lipid NPs [210], Protein-based NPs [211], including NPs synthesized via green synthesis [212].

AgNPs have been successfully used as drug carriers for a multitude of therapeutic medicines a few of which include anti-inflammatory [213, 214], anti-oxidant [215, 216], antimicrobial [217, 218] and anticancer drugs [219, 220].

In the case of AgNCs, they have been additionally customized with Gold metal to produce a Gold-Silver (Au-Ag) hybrid cubic nanoparticle, which has effectively been used in drug delivery process [221].

1.6.1.3 Role in Cancer Treatment:

AgNPs have already demonstrated to be innately antibacterial [222], antiviral [223], antifungal [224], anti-angiogenic [225], anti-inflammatory [226], and even antiplatelet [227].

In accordance with these results, AgNPs were subjected to intensive investigation regarding their role in cancer and have proven to possess intrinsic anticancer activities [228, 229]. They have been tested against different human cancerous cell lines such as endothelial cells [230], IMR-90 lung fibroblasts, U251 glioblastoma cells [231], and MCF7, MDA-MB-231, and MCF 10A breast cancer cells [232].

Their role as carriers of anticancer drugs has been broadly explored and adds to their anticancer treatment [233]. The combined effect of anti-cancerous AgNPs with a known anti-cancer drug has proven to greatly enhance the cytotoxicity of cancer cells, making them more sensitive to the drug and induce apoptosis [234]. Targeted drug therapy using nanocarriers gives access to control the fate of the drug in the body, concomitantly protecting healthy tissues and cells [235].

Although it is preferred that the metal NPs being used for *in vivo* treatment be inert, such NPs may cause bioaccumulation and toxicity. On the contrary, NPs possess the ability to efficiently absorb light energy and convert it to heat energy, which has proven to be a very promising and desirable feature in the treatment of cancer and other such diseases. As a result, metal NPs show promise in hyperthermic tumor therapy (photothermal therapy), where stimulation of NPs via photons produces thermal energy [236].

AgNCs have also demonstrated their functionality in diagnosis and treatment of cancer. They have been tested as potential detectors of lung cancer biomarkers [237], and as biosensors for oral cancer [238].

The biggest contribution of AgNCs in cancer treatment so far, has been their use as templates for the synthesis of Gold Nanocages (AuNCs) [239]. These AuNCs are specifically designed to achieve maximum absorbance of near-infrared wavelength of light for photothermal therapy [240].

These AuNCs have also been used in combination as drug carries and photothermal agents to achieve maximum cancer cell destruction [241].

However, there is still a great need to further investigate AgNCs and their potential role in cancer diagnosis and treatment.

1.6.1.4 Biosensors and Bioimaging:

It is important in the field of medicine to be able to view biomolecules and to understand their physiology and interaction mechanisms [242]. Alongside the general imaging techniques such as X-Rays, Computed Tomography (CT) scans, and Magnetic Resonance Imaging (MRI) and ultrasound, nanoparticle-based contrast agents are being used for bioimaging. On top of that, due to its Surface Plasmon Resonance (SPR), Ag demonstrates unique optical and electronic properties when excited by an external light source [243]. Consequently, the noble metals, Ag and Au, have established a special role as biosensors and in bioimaging. AgNPs have been used to image biomolecules in renal cell carcinoma [244], in the detection of IgG immunoglobulin [245], protein imaging in human bone marrow neuroblastoma cells [246] and more.

Perhaps the most prominent role AgNPs display is in the field of Biosensor and Bioimaging. Along with Ag, AuNPs have also been greatly investigated in this area. This is because metallic NPs offer tunable and unique plasmonic properties that are highly suitable in this regard. AgNPs combined with a biomolecular probe have been very reliable in the sensitivity and stability of target molecule detection [247, 248].

In accordance with the applications of AgNPs in Biosensing and imaging, AgNCs have also played their role in this field and have shown positive outcomes. Their contribution as biosensors for the detection of biomarkers in various cancers has been worthwhile in cancer diagnosis [238]. As

complete optical transparency for AgNPs in tissues is achieved by changing their shape from spheres to hollow cubes, AgNCs have provided great opportunities to be used in optical switching and bioimaging [249].

Nanotechnology is also a rapidly rising research field with great capabilities and promise in various other domains of science such as Physics, Chemistry and Biology. Prodigious amounts of investigation and experimentation are being carried out on the methods of synthesis and practicality of the synthesized NPs. Undeniably, NPs have proven themselves competent and applicable especially in the field of health sciences. Regardless, there is still much need for further inquiry of the effects of shape of NPs. Although scientists are already well aware of all the beneficial attributes of AgNPs, the shape-specific contributions have not yet been clearly delineated. This study focuses on shape specific AgNCs and attempts to demonstrate and elucidate their potential bioactivities by employing them in conventional bioassays.

CHAPTER 2: MATERIALS AND METHODS

2.1 Silver Nanocube Synthesis:

AgNCs were synthesized using two different protocols. The AgNCs thus obtained were characterized using SEM facilities available at LUMS, Lahore and later used in different biological assays. These assays were carried out to determine biological activities and the shelf life of the synthesized AgNCs. Protocols for the synthesis and assessment of the biological activities are narrated in the following sections.

Chemicals: The chemicals used during the present study were either AR or Molecular Biology grade and were purchased from Sigma-Aldrich, Merck, Fluka or corresponding renowned manufacturers.

2.1.1 Synthesis of Silver Nanocubes – Protocol 1 [250]:

To synthesize AgNCs using this protocol an oil bath was set at 150-155°C on a hot plate equipped with magnetic stirring. Ethylene Glycol (EG, 6 ml) was added to a 24 ml vial along with a clean, egg-shaped stir bar. The vessel containing EG was placed in the oil bath for 1 hour and 30 mins. AgNO₃, PVP and Na₂S solutions were prepared as described (Appendix). When the temperature of the solution reached 150-155°C, 100 µl of ~3 mM Na₂S was added. After waiting for 8-9 mins, 1.5 ml PVP was added in two 0.75 ml aliquots. Immediately thereafter, 500 µl (282mM) AgNO₃ was added. The reaction assembly was covered with aluminum foil and left for 20 mins. To stop the reaction, the magnetic hotplate was turned off and the vial was immediately placed in a cool (25°C) water bath to stop the reaction.

2.1.2 Isolation of Nanocubes:

The contents of each vial were transferred to a 15 ml tube. This was followed by rinsing with acetone. The acetone washings were also added to the tube. The tube was centrifuged at 2000 g for 30 mins. The supernatant was discarded, the NP pellet was suspended in 2 ml sterile distilled water and sonicated for 10 mins. The NP suspension was centrifuged again at 9000 g for 20 mins. After repeating these steps for at least 4-5 times, the pellet obtained was finally resuspended in 2 ml sterile distilled water. The tube containing NPs was wrapped in aluminum foil and stored at RT for a definite (7 months) period of time.

2.1.3 Synthesis of AgNCs – Protocol 2 [251]:

Another method mentioned by Bottomley, Prezgot and Ianoul (2012), was used to synthesize AgNCs. A Round Bottom Flask (RBF) carrying 35 ml EG and a clean stir bar was placed in an oil bath set at 150°C for 1 hr with continuous stirring. PVP solution (5 ml) was added to the RBF after heating for 1 hr. Five minutes later, 400 µl of 3 mM Na₂S in EG was added. After another 5 minutes, 2.5 ml of 282 mM AgNO₃ solution in EG was added in a controlled manner. The solution was heated for another 15 minutes. The entire procedure was carried out in the absence of light. Small aliquots of the sample were taken out at regular intervals and diluted with ethanol for UV-visible spectroscopy. The reaction was stopped by placing the RBF in cold (25°C) water bath.

2.1.4 Isolation of Nanocubes:

The prepared solution was diluted with ethanol (1:1 volume) and centrifuged at 6000 rpm for 15 mins. The supernatant was discarded, and the pellet was resuspended via sonication in ethanol. This procedure was repeated 5 times. Two final washings of the sample were done the next day

with sterile distilled water and the sample was stored as 4°C in 4 ml sterile distilled water for a pre-defined time period.

2.1.5 UV-Visible Spectroscopy:

Various dilutions of the prepared sample were prepared and their optical density (OD) was measured at 200-800 nm (UV) range.

2.1.6 Characterization of the nanocubes:

A 10% dilution of both samples was prepared by adding 100 µl of NP solution and 900 µl of deionized water in an Eppendorf tube. This solution was mixed using micropipette. 100 µl of this 10% solution was then extracted and mixed with 900 µl of deionized water in another Eppendorf tube to make a 1% dilution. The prepared samples were sent to LUMS for SEM (Scanning Electron Microscopy with EDX and E-beam Lithograph FEI Nova 450 NanoSEM) characterization.

2.2 Antibacterial Assay:

Antibacterial assay was performed using the Kirby-Bauer disc diffusion method [252]. Seven different species of bacteria were used, namely *Staphylococcus epidermidis* (ATCC 12228), *Staphylococcus aureus* (ATCC 6538), *Bacillus subtilis* (ATCC 6633), *Bacillus pumilus* (ATCC 14884), *Pseudomonas aeruginosa* (ATCC 9027), *Escherichia coli* (ATCC 10536), and *Bordetella bronchiseptica* (ATCC 4617). Four different antibiotic drugs, Ampicillin (A), Ceftriaxone (B), Cefotaxime (C), and Meropenem (D), were used as standards or positive controls. Discs were prepared as follows.

A 10% dilution of AgNP sample was prepared and 10 µl of this dilution was loaded per filter paper disc. In parallel, another set of discs carrying 20 µl of the 10% diluted AgNPs sample was also

prepared. Similarly, discs for all 4 antibiotics were prepared by loading 20 μ l, 10 μ l, or 5 μ l of 10 mg/ml of drug solution per disc. For the combined NPs + Antibiotic discs; against 20 μ l positive control discs, 10 μ l of antibiotics and 10 μ l of the NPs solution were loaded per disc. Blank discs were prepared by loading the discs with sterile water. The discs were air dried and stored at RT.

Spread plate technique was used to culture bacterial lawn in the petri plates. The Petri dishes were sterilized in hot air oven at 110 °C. 15-20 ml Nutrient Agar was poured in each plate and left to solidify. After solidification of agar, ~200-300 μ l of overnight bacterial cultures were spread on the solid agar using a sterilized glass spreader. Standard microbiology techniques were used to avoid contamination. The bacterial cultures were allowed to soak into the agar for about 10-15 minutes after which the discs were placed on the agar surface using forceps according to their pre-determined locations. These plates were placed upside down and left overnight in an incubator at 37°C. Growth and probable subsequent zones of inhibition were examined the next day.

This antibacterial assay was performed with 4 dilutions, 10%, 20%, 30% and 40% of the aged sample and 3 dilutions, 1%, 10% and 30%, of the freshly prepared sample. Our main goal was to determine whether these AgNC samples showed any antibacterial activity at any concentration and whether the aging affects AgNCs antibacterial activity, if any.

2.3 Antioxidant Assays:

2.3.1 FRAP Assay:

FRAP (Ferric Reducing Antioxidant Power) assay was performed to determine the antioxidant properties of the synthesized AgNCs. This assay follows reduction of ferric iron (Fe^{3+}) to ferrous iron (Fe^{2+}) by the antioxidants present in the samples. If the sample contains antioxidants, the mixture color changes to blue, or otherwise remains green.

The assay was conducted in properly labeled Eppendorf tubes. The reaction mixtures were prepared as per the scheme shown in the following Table.

Table 4: Chemicals and their amounts used to carry out FRAP Antioxidant assay.

Ingredients	Positive Control	Test	Negative Control
Ascorbic acid (1%)	100 μ l	-	-
NP dilution or original	-	100 μ l	-
Water	-	-	100 μ l
0.2 M Phosphate Buffer pH 6.6	250 μ l	250 μ l	250 μ l
Potassium ferricyanide (1%)	250 μ l	250 μ l	250 μ l
Total	600 μ l	600 μ l	600 μ l

During the assay, 4 (v/v) dilutions of NCs sample (1%, 10%, 20% and 40%) were tested. Ascorbic acid (1%) was used as the positive control, while water was used as the negative control.

The reaction tubes were incubated at 50°C for 20 mins. After the incubation, 250 μ l of 10% (w/v) TCA was added to each tube. The tubes were centrifuged at 1350 RPM for 20 mins. The supernatant then obtained was collected from each tube and processed as follows for Absorbance or Optical Density (OD) measurement.

Table 5: Chemicals and their amounts used to carry out FRAP Antioxidant assay.

Ingredients	Volume
Supernatant	250 μ l
Distilled water	250 μ l
FeCl ₃ (0.1% w/v)	50 μ l

OD of the reaction mixture was determined at 700 nm using an ELISA plate reader.

2.3.2 DPPH Assay:

The DPPH (1,1-diphenyl-2-picrylhydrazyl) assay was performed to determine the antioxidant activity of the samples. This method was adopted from Shimada et al., [253] and optimized.

DPPH solution (90 μ l of 0.3 mM) and the sample solution (10 μ l) were mixed and incubated for 30 min in the dark at room temperature. The absorbance of this solution was measured at 517 nm using an LT-4500 96-well microplate reader, Labtech UK. Absorbance of the blank and the standard were also measured in the same way. These tests were performed in triplicates. The percentage of total inhibition of DPPH radicals was calculated using the equation given below.

$$\text{Inhibition (\%)} = \frac{\text{Absorbance of the blank} - \text{Absorbance of the sample}}{\text{Absorbance of the blank}} \times 100$$

Absorbance of the blank

Antioxidant activity of a suitable dilution of each active sample was determined and IC₅₀ values were calculated using EZ-Fit Enzyme Kinetics Software (Perrella Scientific Inc. Amherst, USA).

2.4 Hemolytic Activity:

The purpose of performing the hemolytic activity was to determine whether AgNCs possess the ability to destroy erythrocytes. Previous studies [254] have shown that AgNPs are hemolytic in nature, but their hemolytic effect is generally lower as compared to their antibacterial capabilities. As is the case with their antimicrobial activity, the hemolytic property of AgNPs is affected by different parameters/physiologic characteristics of the AgNPs especially their size [255].

The synthesized AgNCs were assessed for their hemolytic activity using the methods described elsewhere [256, 257]. Freshly obtained heparinized bovine blood (93 ml) was collected from the Department of Clinical Medicine and Surgery, University of Agriculture, Faisalabad, Pakistan. The blood was centrifuged for 5 min at 1000 x g. The plasma was discarded, and the obtained cells were washed three times with 5 ml chilled (4°C) sterile isotonic Phosphate-Buffer Saline (PBS) pH 7.4 every time. The erythrocytes were maintained at 10⁸ cells per ml for each assay. Each AgNC suspension (100 µl original or a dilution) was mixed with human erythrocytes 10⁸ cells/ml and tested separately. Samples were incubated for 35 min at 37°C and agitated after every 10 min. Immediately after incubation, the samples were placed on ice for 5 min and then centrifuged for 5 min at 1000 x g. The supernatant (100 µl) was taken from each tube and diluted 10 times with chilled (4°C) PBS. Triton X-100 (0.1% v/v) was taken as the positive control and PBS was taken as the negative control. Both the controls were passed through the same process.

The absorbance was measured at 576 nm. The percentage of RBCs lysis was calculated for each sample using the following formula.

$$\text{Percentage hemolysis} = \frac{\text{Absorbance of the sample} - \text{Absorbance of the blank}}{\text{Absorbance of the positive control}} \times 100$$

2.5 Anti-inflammatory Activity:

AgNPs and NCs are generally known for their destructive and cytotoxic properties. By performing the anti-inflammatory assay on AgNCs, we aimed to discover the reduction of inflammation, if any, caused by our AgNCs. A study had shown the nanocrystalline silver to be anti-inflammatory in nature as it helps in improving the overall healing process [258]. Various green synthesized AgNPs have been tested for their anti-inflammatory activity and results have been very promising [259, 260]. However, the anti-inflammatory effect of AgNPs has not been investigated thoroughly as opposed to their inflammatory response.

For the evaluation of anti-inflammatory activity of AgNCs, 0.2% (w/v) stock solution of Bovine Serum Albumin (BSA) was prepared in tris-buffer saline and the pH was adjusted from pH 8.53 to pH 6.74 using glacial acetic acid. For each assay two replicates of 500 μ l of one of these BSA stock solutions were pipetted and 5.0 μ l of the test material, AgNC suspension, in methanol was added to the BSA solution. The control consisted of 500 μ l BSA with 5 μ l methanol. The samples were heated at 72°C for 5 min in 2.0 ml Eppendorf tubes in metal racks, followed by cooling for 20 min under laboratory conditions. The absorbance was read using a Spectrofluorimetric wavelength parameter of Ex 480/Em 520 in 1.0 ml glass cuvettes or at 660 nm in a Spectrophotometer. The percentage inhibition of precipitation (stabilization of the protein) was determined on a percentage basis relative to the controls as in the following equation.

$$\text{Precipitation inhibition (\%)} = \frac{\text{Absorbance of the control} - \text{Absorbance of the sample}}{\text{Absorbance of control}} \times 100$$

According to the assay mentioned above, samples/compounds that inhibited denaturation with a percentage greater than 20% over a range of concentrations were regarded as those having anti-inflammatory qualities [261].

2.6 Biofilm Inhibition Assay using Microtiter-plate method:

Some microorganisms, such as bacteria, fungi and protists, tend to form a layer of growth known as biofilm. These complex communities are resistant to general antibiotics and are the cause of more chronic pathogenesis [262]. AgNPs have already proven to be antibacterial in nature and as anticipated they are a great alternative against biofilms [263]. As for the effect of shape on the antibiofilm property of AgNPs, a recent study suggests that AgNCs show a more pronounced effect when compared to their spherical counterparts [264].

The biofilm formation was accomplished using method described elsewhere [265, 266]. In a sterile 96-well flat-bottomed plastic tissue culture plate wells were filled with 100 μ l of nutrient broth (Oxoid, UK), 100 μ l testing sample and 20 μ l of bacterial suspension. The positive control wells contained 100 μ l of nutrient broth and 20 μ l of bacterial suspension whereas the negative control wells contained nutrient broth only. The plates were covered and incubated aerobically for 24 hours at 37°C. The content of each well was washed three times with 220 μ l of sterile phosphate buffer. The plates were vigorously shaken in order to remove all non-adherent bacteria. The remaining attached bacteria were fixed with 220 μ l of 99% methanol per well, and after 15 min plates were emptied and left to dry. The plates were then stained for 5 min with 220 ml of 50% crystal violet per well. Excess stain was rinsed off by placing the plate under running tap water.

MATERIALS AND METHODS

After the plates were air dried, the dye bound to the adherent cells was resolubilized with 220 μ l of 33% (v/v) glacial acetic acid per well. The OD of each well was measured at 630 nm using microplate reader (BioTek, USA) according to the methods described elsewhere [267]. All the tests were carried out in triplicate against the selected bacterial strains and the results were averaged. The bacterial growth inhibition (INH%) was calculated as follows;

$$\text{INH \%} = \frac{100 - \text{OD}_{630 \text{ sample}}}{\text{OD}_{630 \text{ control}}} \times 100$$

$\text{OD}_{630 \text{ control}}$

CHAPTER 3: RESULTS AND DISCUSSION

Synthesis of metal NPs and their applications have emerged as one of the most active areas of scientific investigation. The growing body of data suggests that these particles have unique characteristics and have a wide range of applications particularly in the area of life sciences. As the data accumulates, the focus is shifting towards synthesis of metal NPs having a pre-determined shape and use of these uniquely shaped particles in biological systems as an attempt to improve the efficacy and usefulness of these micro sized entities. During the present study AgNCs were synthesized, characterized through electron microscopy and checked for a variety of applications through various assays to assess their potential biological activities. Results of all the assays were recorded to assess usefulness of these specifically shaped NPs. In addition, a comparison between aged AgNCs and freshly synthesized AgNCs was done to determine whether AgNCs lose their biological activities after storage for a specific period of storage.

3.1 Synthesis of Nanoparticles:

AgNCs were synthesized using a chemical reduction process known as the polyol synthesis method. Different shapes of AgNPs can be achieved using variations of the polyol method (Fig. 3). Our aim was to achieve cubic shape so as to investigate and evaluate their effect, if any, in various bioassays. Realistically, producing specific silver nanostructures in a laboratory is a challenging task [268]. We used two slightly altered variations of the polyol process [250, 251]. The optical density (OD) of the prepared solution was measured at 200-800 nm (UV) range using a UV-Visible Spectrophotometer.




Figure 1: Optical Density of freshly prepared AgNCs sample using UV-Visible Spectrophotometer.

S.E.M. results were acquired using the facility available at LUMS University, Lahore. The samples were characterized immediately after synthesis (Figures 2-5). Cubic nanostructures were noticeably visible in the first batch synthesized, clumps and clusters appearing in the second batch probably indicate a lack of sonication before SEM imaging. We conclude that while both the methods can produce nano cubes, the second method [251] is more efficient in producing bulk of these specifically shaped AgNPs. For aging, a part of the synthesized nano cubes were stored at room temperature for about 7 months. Later, results of the biological assays of the fresh and the aged samples were compared to determine shelf life and effect of storage on these NPs.




Figure 2 (A, B, C, D): S.E.M results of Silver NanoCubes synthesized using polyol synthesis showing silver nanocubes with curved edges.




Figure 3 (A, B, C, D): S.E.M results of Silver NanoCubes synthesized using polyol synthesis shows a miscellany of shapes.




Figure 4 (A, B): S.E.M results of Silver NanoCubes synthesized using polyol synthesis shows a miscellany of shapes.




Figure 5 (A, B, C, D): S.E.M results of freshly prepared Silver NanoCubes synthesized using polyol synthesis shows a miscellany of shapes. Sample was subjected to S.E.M after storage for 1 month. No sonication before S.E.M was carried out.

3.2 Activities of Synthesized Nanocubes:

Synthesized NPs were subjected to various tests to assess their contribution in bioassays. An attempt was also made to analyze the effect of storage on the activity of the aged sample and the fresh sample.

AgNCs were examined for;

1. Antibacterial Activity
2. Antioxidant Activity

- a. FRAP Assay
- b. DPPH Assay
3. Hemolytic Activity
4. Anti-inflammatory Activity
5. Biofilm Inhibition Activity

Results of these assays are discussed in the following sections.

3.2.1 Antibacterial Activity:

Antibacterial activity of AgNCs was determined in triplicate using seven different bacterial strains viz., *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Bacillus subtilis*, *Bacillus pumilus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Bordetella bronchiseptica*. Four different antibacterial drugs, Ampicillin (A), Ceftriaxone (B), Cefotaxime (C), and Meropenem (D), were used as standards or positive controls.

Silver metal has long been known to be innately antibacterial in nature [269] and its nanosized counterparts are no exception. Despite the fact that a comprehensive detailed account of the antibacterial mechanism of action of AgNPs is still not known, a few theories have been proposed. Potentially three different mechanisms are speculated to take place for an antibacterial effect. One, release of silver ions (Ag^+) from the NPs, uptake of said ions by cell, followed by disruption of the ATP cycle and DNA replication. Two, generation of Reactive Oxygen Species (ROS) by AgNPs and (Ag^+), and three, rupturing of cell membranes by AgNPs [270] to kill the bacteria.

Other factors have also been reported to play a role in the antimicrobial potential of AgNPs. Studies have shown that AgNPs with a smaller size [271] and spherical shape [272] display greater

antibacterial prowess. Generally, AgNPs with size smaller than 10 nm have been observed to release greater amounts of Ag⁺ (due to larger surface area) which would impact the antibacterial effect. Relatively, in AgNPs with size greater than 10 nm a lower concentration of Ag⁺ is released and in this case the NPs themselves carry out the antibacterial effect [273]. Furthermore, the surface modifications of AgNPs can cause a change in their antibacterial effect [274], generally, by stabilizing the AgNP and altering Ag⁺ release. However, in doing so the antibacterial activity is in turn affected by the nature of the capping/modifying agent as well as the surrounding media [275]. It has been suggested that the AgNPs are toxic to both human and bacterial cells albeit with different mode of toxicity. It is believed that in human cells the entirety of the NP is taken up by the cell which leads to cytotoxicity whereas, in the case of bacteria the dissolved Ag⁺ are believed to be the toxic components [276].

Our aim for this study was to assess whether AgNCs showed any antibacterial activity using different concentrations of the synthesized AgNCs as, to our knowledge, little is known regarding this particular shape. It is however known that the size and facets of AgNCs play an important role in deciding the magnitude of the antibacterial capability [195, 277]. The aged AgNCs sample showed no antibacterial activity in all seven species of the bacteria tested against any dilution of AgNCs (Figure 6). The positive control showed clear zones of inhibition indicating susceptibility of bacteria to the antibiotic and exhibiting no signs of antibiotic resistance. The combination discs, antibiotic + AgNCs, also showed a zone of inhibition with radius equal to that of positive control suggesting that the AgNCs had no synergistic or antagonistic contribution towards the effect of the antibiotic. It has been reported that the antibacterial activity of AgNPs lasts for 8-13 months [278] but we cannot ignore the size, shape, synthesis method and storage conditions of the AgNPs in their experiment.

The freshly synthesized AgNCs sample showed no antibacterial activity against 6 out of seven species of bacteria used (Figure 7-12). *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Bacillus pumilus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Bordetella bronchiseptica* all were resistant to 10 μ l and 20 μ l of the 10% dilution of fresh AgNCs tested. Antibiotic discs (5 μ l loaded) showed clear zones of inhibition indicating no resistance to the drug. Zones of inhibition were observed in the antibiotic + AgNCs discs, but their size was equivalent to the one produced by positive control, indicating no synergistic or antagonistic effect of the AgNCs towards the antibiotic drug. Further tests using a 1% and 30% dilution of the AgNCs were carried out in an attempt to determine if a change in concentration of AgNCs would have any discrete effect on the antibacterial test. As evident from Figure 13, neither 1% nor 30% dilutions showed any antibacterial activity. These results hint at some form of resistance from the bacterial species against AgNCs.

Bacillus subtilis was the only strain that displayed sensitivity to AgNCs discs. Figure 14 exhibits the effect of 10 μ l and 20 μ l of 10% AgNCs. It also indicates that the discs containing 10 μ l of the 10% dilution are more potent than 20 μ l of 10% dilution. The antibiotic drugs showed clear zones of inhibition and the combination of drug + AgNCs had zones similar in size to those of positive control indicating no synergistic or antagonistic effect of AgNCs.

Keeping in mind *B. subtilis* was more susceptible to 10 μ l of 10% AgNCs, the experiment was extended to see if a change in concentration would show any distinct change in the effect. AgNCs discs loaded with 10 μ l of a 1% and 30% dilution of freshly prepared sample were made and tested. It is evident in Figure 15 that 1% dilution had a greater effect than 30% dilution of AgNCs.

Our results suggest that in general, the bacterial strains possess some kind of resistance to the antibacterial activity of Ag nano cubes. This may either be related to the shape and size of the nano

particles, release of the Ag⁺ ions from the nano cubes, uptake of the Ag⁺ ions/nano cubes through the bacterial cell wall/cell membrane or a combination of the various mechanisms. Bacteria that are susceptible to the AgNCs exhibit a better sensitivity at lower concentration of AgNCs rather than a higher concentration. This observation hints at some kind of uptake mechanism that becomes saturated at the higher concentrations. This hypothesis however needs to be further investigated through experimentation. We also conclude that over time AgNPs “age” which has a toll on their physicochemical and biological properties as described in some earlier studies [193]. We also hypothesize that different strains of bacteria have different modes of susceptibility for AgNCs. Nonetheless, a great deal of research is needed to fully understand and acknowledge the mechanism that takes place during antibacterial action of AgNCs.




Figure 6 (A, B, C, D): Evaluation of the antibacterial activity of the aged AgNPs using *S. aureus* (Gram-positive) (A, B) and *S. epidermidis* (Gram-positive) (C, D). NC, the Negative Control disc, was placed in one corner of the plates. Antibiotic discs C (Cefotaxime) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l of a 30% and a 40% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 7 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *P. aeruginosa* a Gram-negative bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DA (Ampicillin), DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l (10) and 20 μ l (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 8 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *B. pumilus* a Gram-positive bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DA (Ampicillin), DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l (10) and 20 μ l (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 9 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *B. bronchiseptica* a Gram-negative bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DA (Ampicillin), DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 µl 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 µl (10) and 20 µl (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 10 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *S. aureus* a Gram-positive bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l (10) and 20 μ l (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 11 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *E. coli* a Gram-negative bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DA (Ampicillin), DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l (10) and 20 μ l (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 12 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *S. epidermidis* a Gram-positive bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DA (Ampicillin), DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l (10) and 20 μ l (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 13 (A, B, C, D): Evaluation of the antibacterial activity of freshly prepared AgNPs using 6 bacterial strains *E. coli* (A), *S. epidermidis* (B), *B. bronchiseptica* (C), *S. aureus* (D), *B. pumilus*, and *P. aeruginosa*. NC, the Negative Control disc, was placed in one section of the plate. Antibiotic discs B (Ceftriaxone) carrying 5 μ l 10 mg/ml of the antibiotic was used as the positive control. Discs carrying 10 μ l of a 30% (30) and 1% (1) nanoparticles solution were used as test. To determine any antibacterial activity, these discs were used in triplicate.




Figure 14 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *B. subtilis* a Gram-positive bacterium. NC, the Negative Control disc, was placed in the middle of the plate. Antibiotic discs DA (Ampicillin), DB (Ceftriaxone), DC (Cefotaxime) or DD (Meropenem) carrying 10 μ l 10 mg/ml of the respective antibiotic were used as the positive controls. Discs carrying Nanoparticles present in 10 μ l (10) and 20 μ l (20) of a 10% solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.




Figure 15 (A, B, C, D): Evaluation of the antibacterial activity of the freshly synthesized AgNPs using *B. subtilis*. NC, the Negative Control disc was placed in the middle of the plate. Antibiotic discs A (Ampicillin), B (Ceftriaxone), C (Cefotaxime), D (Meropenem) carrying 5 μ l 10 mg/ml of the respective antibiotics were used as the positive controls. Nanoparticle discs carrying 10 μ l of 1% (A,B) and 30% (C,D) solution were used as the test. In addition, N+D discs carrying NPs and the respective antibiotic were used to evaluate any synergistic or antagonistic effect of the NPs.

3.2.2 Antioxidant Activity:

Countless AgNPs synthesized via green synthesis method have been evaluated for their antioxidant activity [279, 280] and have shown excellent antioxidant activity. Comparative studies of the antioxidant potential between green synthesized and chemically synthesized AgNPs highlight that the green synthesized AgNPs possess far greater antioxidant capabilities as compared to AgNP produced by chemical synthesis [281, 282]. This increase in antioxidant activity displayed by green synthesized AgNP is thought to be a result of surface modifications of the AgNP caused by phytochemicals. Interestingly, the published literature lacks any reports regarding antioxidant potential of the AgNCs or the mechanisms involved therein. Ours is therefore among the first reports regarding the antioxidant potential of AgNC, if any. Antioxidant potential of our AgNCs was determined using two different and very popular antioxidant assays, i.e, FRAP assay and the DPPH assay.

1. FRAP Assay

The FRAP antioxidant assay was performed in triplicate to determine the antioxidant activity (if any) of AgNCs. Table 6 shows the results obtained from a 40% dilution of the aged AgNCs. The absorbance values of the 40% dilution were parallel to the Negative control suggesting no antioxidant activity. However, a notable antioxidant activity pattern was observed when the 1%, 10% and 20% dilutions of the freshly prepared AgNCs were examined for their antioxidant activities. In Figure 16, we can see the distinct color changes observed for negative control, positive control and the three different dilutions of AgNCs tested. Table 7 displays the absorbance values of these samples at 700 nm. There is a clear increase in the antioxidant activity of AgNCs as the samples become more concentrated.

As such, a highly concentrated sample such as a 40% dilution, should have shown a high value of antioxidant activity. The absence of antioxidant activity in the aged sample is vindicated by the age of the sample. Since it is expected that the Ag⁺ ions trapped inside the AgNCs would serve as the active antioxidant component, we postulate that either these ions get completely lost due to reduction in the aged samples or they get trapped in the nanocubes debris of the aged particles. On the contrary, the fresh nanocubes not only retain and protect these active ingredients they also release these ions in the assay conditions effectively.

Table 6: Antioxidant activity of the aged NPs using FRAP assay.

Sample	Absorbance at 700 nm	Absorbance at 700 nm	Absorbance at 700 nm
Negative (Water)	0.373	0.329	0.305
Ascorbic Acid	overflow	overflow	Overflow
Aged sample 40%	0.372	0.406	0.300




Figure 16: Evaluation of the antioxidant potential of the nanoparticles using FRAP assay. Lane A (Well 1-3) Negative Control. Lane B (Well 1-3) Positive Control. Lane C (Well 1-3) 1% solution of freshly prepared NPs. Lane D (Well 1-3) 10% solution of freshly prepared NPs. Lane E (Well 1-3) 20% solution of freshly prepared NPs.

Table 7: Antioxidant activity of the freshly synthesized NPs using FRAP assay.

Sample	Absorbance at 700 nm	Absorbance at 700 nm	Absorbance at 700 nm
Water (negative)	0.346	0.316	0.326
Ascorbic Acid	overflow	Overflow	overflow
1% (NS)	0.280	0.320	0.293
10% (NS)	0.958	0.967	1.012
20% (NS)	1.894	1.937	1.885

2. DPPH Assay:

Additionally, DPPH assay was also performed on both AgNC samples to assess their antioxidant prowess. Table 8 assuredly demonstrates the same results as indicated by the FRAP assay. The aged sample, regardless of the concentration, showed little to no antioxidant activity whereas the freshly prepared sample showed high levels of antioxidant activity with the increasing concentration of the AgNC sample. Just as a comparison the 10% dilution of the old sample gave a value of 2.1 which is less than the value of 2.7 presented by even the 1% diluted fresh sample.

Table 8: Antioxidant activity of the AgNPs (aged and fresh) using DPPH assay*.

Sample	Concentration (%)	Antioxidant activity (%)
1. Aged Sample	10	2.1
	20	1.9
	30	2.4
	40	3.2
2. Fresh Sample	1	2.7
	10	21.19
	20	45.38
Quercetin (0.5 mM)		85.65±0.15
Propyl gallate (0.5 mM)		80.71±0.14

*Four concentrations of the aged sample were used (10%, 20%, 30% and 40%). Three concentrations of the fresh sample (1%, 10% and 20%) were used.

Our assessment of the antioxidant activity of AgNCs synthesized via polyol method have displayed stimulating results. The aged AgNCs, as in the case of antibacterial activity, have lost their antioxidant activity as well. The freshly prepared AgNCs sample has shown antioxidant activity directly proportional to the increasing concentration used. As little work has been done to evaluate the antioxidant activity of AgNCs, we can confidently say that the shape of the NP helps to protect the antioxidant activity of the active ingredient i.e., Ag⁺ ions although further studies need to be carried out in order to understand and elucidate the mechanisms associated with the change in the extent of antioxidant activity.

3.2.3 Hemolytic Activity:

Taking into consideration the future use of AgNPs in medicine, it is inevitable that these particles will be coming into direct contact with erythrocytes. The hemolytic activity of AgNCs was therefore performed to determine their toxicity, if any, towards Red Blood Cells (RBC). The hemolytic assay performed on our AgNCs showed little to no hemolytic activity, with negligible deviation suggesting some kind of inertness towards hemolysis (Table 9). This estimation was conducted in reference to 0.01% Triton-X 100, the positive control, that exhibited 99% hemolytic activity.

Previous studies conducted on AgNPs have suggested that the hemolytic activity of AgNPs is size dependent. Smaller AgNPs, with size 15 nm, were observed to be more hemolytic in nature. The RBC damaging property has been attributed to the direct interaction of the nanoparticles with the RBCs [255]. Another study compared the cytotoxic effect of different shapes of AgNPs on RBCs. Between spherical and wire shaped AgNPs of different sizes, the size and dose of the particles proved to be a greater contributing factor in the hemolytic activity rather than the shape [283]. As a result, AgNPs of a specific size, preferably a size large enough to exhibit inertness towards

RBCs, present great potential for use inside the body. The lack of hemolytic activity displayed by our AgNCs can be ascribed to the size of the NPs and it appears that these cubes are safe to use as carriers of a drug for targeted drug delivery. This preliminary observation, however, needs to be investigated in detail through further experimentation.

Table 9: Hemolytic activity of the AgNCs.

Sample	% Hemolysis	Standard Deviation
AgNCs (20 μ l)	4.72813238770686	0.057888
0.01% Triton-X 100 (20 μ l)	99.05437352	0.06477

3.2.4 Anti-inflammatory Activity:

The beneficial properties, if any, of AgNPs for human health were further evaluated by conducting anti-inflammatory test. This activity is performed to determine if a substance reduces inflammation and as such encourage the healing process. Our results, shown in Table 10, indicate that AgNCs possess a relatively strong anti-inflammatory activity. While under our assay conditions the positive control, Diclofenac sodium, causes 74% reduction in the inflammation, our test material, the AgNCs, remarkably reduce inflammation by 62%. Thus, these silver nanocubes have the potential of being used as anti-inflammatory agents.

Through a study in porcine models, nanocrystalline silver has been demonstrated to possess remarkable anti-inflammatory properties [258]. This study showed an increase in inflammatory cell apoptosis, decrease in proinflammatory cytokines expression and a decrease in gelatinase

activity, all presumed to be directly caused by nanocrystalline silver. Similarly, another study has revealed the anti-inflammatory characteristic of green synthesized AgNPs both *in vitro* and *in vivo*, highlighting in both cases decrease in levels of cytokines, in addition to advocating their potential use in the treatment of psoriasis vulgaris skin lesions [259]. In accordance with these findings, AgNPs/nanocrystalline silver has been used extensively in wound dressings to facilitate healing of the wound [284, 285]. Further experimentation is needed to ascertain whether AgNCs are more potent anti-inflammatory mediators compared to other Ag nanomaterials.

Table 10: Anti-inflammatory activity of the AgNCs.

Sample	% Anti-inflammatory activity	Standard Deviation
AgNCs (20 μ l)	62.4203821656051	0.086767
Diclofenac sodium (20 μ l) conc. 10 mg/mL	74.37	0.05698

3.2.5 Biofilm Inhibition:

Bacterial species are among the most adaptable life forms on earth. They can exist as individual cellular structures or, as a survival mechanism, these micro-organisms can form complex 3-dimensional multilayered structures referred to as biofilms on biological or non-biological surfaces by secreting various extracellular polymeric substances (EPS) [286]. Biofilms can be a result of a single species as well as a mixture of different species of bacteria. The type of bacterial strain(s) and different environmental factors play a role in determining the varying physicochemical properties of these biofilms [287]. Following the irreversible attachment and colonization of

bacterial species on a solid surface, rapid bacterial cell growth takes place and EPS is produced resulting in the formation of a biofilm [288]. These biofilms are a cause of various chronic diseases of the auditory system [289], the circulatory system [290], the digestive system [291], the integumentary system [292], the reproductive system [293], the respiratory system [294], and the urinary system [295]. They may even lead to some forms of cancers [296]. Biofilm inhibitors therefore have a beneficial potential for the treatment of bacterial infections. With the increase in bacterial resistance towards antibiotics, lack of availability of novel antimicrobial chemicals and the protective EPS layer provided by the biofilms, researchers have directed their attention towards nanotechnology and its possible therapeutic applications against microbial infections [297-302]. Regardless of these variations, all biofilms share some common properties, the most familiar of which is their tendency to interact, specifically or non-specifically, with living or non-living surfaces in an effort to become sessile [303]. Metallic nanoparticles show great promise in altering the metabolic activity of bacteria [304] and hence hold potential as a form of treatment of bacterial diseases. Amongst these, AgNPs particularly have been seen to enter biofilms and suppress the genes that allow for biofilm formation, consequently preventing biofilm formation [305]. This antibacterial property is generally considered to be a result of released Ag ions.

During our experiments performed on *Bacillus subtilis*, our AgNCs gave a 43.6% biofilm inhibition with a standard deviation of ± 0.04 (Table 11). These results substantiate previous findings that AgNPs are good inhibitors of biofilm formation and suggest that the shape of NPs has little effect on their inhibitory activity. This may be because the main element responsible for biofilm inhibition is the Ag ions and not the AgNPs itself.

Table 11: Biofilm inhibition of the AgNCs performed on *Bacillus subtilis*.

Sample	% Biofilm Inhibition	Standard Deviation
AgNCs (100 μ l)	43.6363636363636	0.04532
Ciprofloxacin (100 μ L) conc. 10 mg/mL	61.8181818181818	0.05643

Conclusion

The aim of the present investigation was to synthesize AgNCs and assess their potential for use in health biotechnology. AgNCs were successfully synthesized using polyol reduction method and characterized via SEM. They were assessed for a number of biological properties including antibacterial prowess, antioxidant activity, hemolytic activity, anti-inflammatory activity and biofilm inhibition activity. Overall our results are analogous to previous studies performed on AgNPs, mainly because the biological properties of AgNPs are affected mostly by their size and the ability to release Ag^+ rather than the shape of the particle [306].

In some cases, such as in hemolytic assays, a larger size for AgNPs is preferred as it renders them inert towards RBCs. Other activities such as anti-oxidant and anti-inflammatory activities of AgNCs require comprehensive studies to be carried out before any further conclusions can be drawn. According to the literature the antibacterial activity is the most extensively studied property of the AgNPs, but surprisingly the exact mechanism of action that takes place is still not known. Undeniably, AgNPs are highly antibacterial in nature, but even the slightest alteration in size,

shape, surface modification, and even NP facets appear to produce a drastic difference in the magnitude of antibacterial activity. Similarly, the ability to inhibit biofilm synthesis is an extensively studied parameter, and it is mainly affected by the ability of the AgNPs to release Ag⁺. We know from previous studies that AgNPs with smaller size have greater biofilm inhibiting ability as the larger surface area allows for greater Ag⁺ release.

Our results indicate that the AgNCs possess great potential for use in medicine. Nonetheless there is great need for further experimentation to elucidate in detail exact mechanisms of the observed characteristics and validation of their beneficial properties over AgNPs in other shapes. It is therefore suggested that studies be planned to work out these mechanism in details. AgNPs be prepared in different shapes and tested for their biological activities. We can ask that if the AgNPs are formed after reduction of the Ag⁺ ions into metallic silver, then how do these NPs exert their activities through the release of Ag⁺ ions as suggested by several workers [307]. It has been proposed that the silver NPs undergo an oxidative dissolution generating Ag⁺ ions, a process that may either involve H₂O₂ or Oxygen. If true, the AgNPs would be expected to be gradually converted back into ionic silver and lose their activities. Our results coincide with this speculation as the newly synthesized and the stored old NPs vary in their characteristics significantly. The NP's size to shape ratio is another interesting parameter that needs to be studied thoroughly. Is it possible to prepare NPs having a specific shape in varying sizes and if so, what will be the effect(s) of these size variations on the properties of these NPs? Answers to such questions can provide us very important information about the NPs in general and AgNPs and AgNCs, in particular. The information thus obtained can then be explored for the potential use of these NPs in health biotechnology to avail their beneficial effects for humanity.

References:

1. Schellauf, F., *15 Regulation of Nanomaterials*. Nanocosmetics: From Ideas to Products, 2019: p. 337.
2. Feynman, R.P., *There's plenty of room at the bottom*. California Institute of Technology, Engineering and Science magazine, 1960.
3. Cartaxo, A., *Nanoparticles types and properties–understanding these promising devices in the biomedical area*. 2010, MS thesis, Dept. Biomed. Eng., University of Minho., Braga, Portugal.
4. Anu Mary Ealia, S. and M.P. Saravanakumar, *A review on the classification, characterisation, synthesis of nanoparticles and their application*. IOP Conference Series: Materials Science and Engineering, 2017. **263**: p. 032019.
5. Carvalho, M., R. Reis, and J.M. Oliveira, *Dendrimer nanoparticles for colorectal cancer applications*. Journal of Materials Chemistry B, 2020. **8**(6): p. 1128-1138.
6. Husseini, G.A. and W.G. Pitt, *Micelles and nanoparticles for ultrasonic drug and gene delivery*. Advanced Drug Delivery Reviews, 2008. **60**(10): p. 1137-1152.
7. Movassaghian, S., O.M. Merkel, and V.P. Torchilin, *Applications of polymer micelles for imaging and drug delivery*. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2015. **7**(5): p. 691-707.
8. Haghirsadat, F., et al., *A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines*. Cell J, 2017. **19**(Suppl 1): p. 55-65.
9. Malam, Y., M. Loizidou, and A.M. Seifalian, *Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer*. Trends in Pharmacological Sciences, 2009. **30**(11): p. 592-599.
10. Wang, Z., et al., *Functional ferritin nanoparticles for biomedical applications*. Frontiers of Chemical Science and Engineering, 2017. **11**(4): p. 633-646.
11. Thakral, S. and R. Mehta, *Fullerenes: An introduction and overview of their biological properties*. Indian journal of pharmaceutical sciences, 2006. **68**(1): p. 13.
12. Iijima, S., *Helical microtubules of graphitic carbon*. Nature, 1991. **354**(6348): p. 56-58.
13. Zou, L., et al., *Fabrication of a Spherical Superstructure of Carbon Nanorods*. Advanced Materials, 2019. **31**(24): p. 1900440.
14. Kumar, A., et al., *Formation and characterization of carbon nanowires*. Journal of Applied Physics, 2007. **102**(4): p. 044305.
15. Hammel, E., et al., *Carbon nanofibers for composite applications*. Carbon, 2004. **42**(5): p. 1153-1158.
16. McNamara, K. and S.A.M. Tofail, *Nanoparticles in biomedical applications*. Advances in Physics: X, 2017. **2**(1): p. 54-88.
17. Huang, X. and M.A. El-Sayed, *Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy*. Journal of Advanced Research, 2010. **1**(1): p. 13-28.
18. Gerber, A., et al., *Gold nanoparticles: recent aspects for human toxicology*. Journal of Occupational Medicine and Toxicology, 2013. **8**(1): p. 32.

19. Das, B., et al., *Surface modification minimizes the toxicity of silver nanoparticles: an in vitro and in vivo study*. JBIC Journal of Biological Inorganic Chemistry, 2017. **22**(6): p. 893-918.
20. Li, X.G., et al., *Hybridization and Characteristics of Fe and Fe–Co Nanoparticles with Polymer Particles*. Nano Letters, 2001. **1**(9): p. 475-480.
21. Suh, Y.J., et al., *Size-controlled synthesis of Fe–Ni alloy nanoparticles by hydrogen reduction of metal chlorides*. Powder Technology, 2006. **161**(3): p. 196-201.
22. Ahmed, J., et al., *Bimetallic Cu–Ni nanoparticles of varying composition (CuNi₃, CuNi, Cu₃Ni)*. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2008. **331**(3): p. 206-212.
23. Sun, S., et al., *Controlled Synthesis and Assembly of FePt Nanoparticles*. The Journal of Physical Chemistry B, 2003. **107**(23): p. 5419-5425.
24. Seehra, M., et al., *Size-dependent magnetic parameters of fcc FePt nanoparticles: applications to magnetic hyperthermia*. Journal of Physics D: Applied Physics, 2010. **43**(14): p. 145002.
25. Yang, H., et al., *Monodisperse water-soluble Fe–Ni nanoparticles for magnetic resonance imaging*. Journal of alloys and compounds, 2011. **509**(4): p. 1217-1221.
26. Fuchigami, T., et al., *A magnetically guided anti-cancer drug delivery system using porous FePt capsules*. Biomaterials, 2012. **33**(5): p. 1682-1687.
27. Moghimi, N. and K. Leung, *FePt alloy nanoparticles for biosensing: enhancement of vitamin C sensor performance and selectivity by nanoalloying*. Analytical chemistry, 2013. **85**(12): p. 5974-5980.
28. Tong, S., H. Zhu, and G. Bao, *Magnetic iron oxide nanoparticles for disease detection and therapy*. Materials Today, 2019. **31**: p. 86-99.
29. Karimi, Z., L. Karimi, and H. Shokrollahi, *Nano-magnetic particles used in biomedicine: Core and coating materials*. Materials Science and Engineering: C, 2013. **33**(5): p. 2465-2475.
30. Gupta, S.M. and M. Tripathi, *A review of TiO₂ nanoparticles*. Chinese Science Bulletin, 2011. **56**(16): p. 1639.
31. Ali, M.M., et al. *Optical properties of cerium oxide (CeO₂) nanoparticles synthesized by hydroxide mediated method*. in *AIP Conference Proceedings*. 2018. AIP Publishing LLC.
32. Balogh, D., et al., *Programmed synthesis by stimuli-responsive DNAzyme-modified mesoporous SiO₂ nanoparticles*. Angewandte Chemie, 2015. **127**(40): p. 11818-11822.
33. Padmavathy, N. and R. Vijayaraghavan, *Enhanced bioactivity of ZnO nanoparticles—an antimicrobial study*. Science and technology of advanced materials, 2008.
34. Volkov, Y., *Quantum dots in nanomedicine: recent trends, advances and unresolved issues*. Biochemical and Biophysical Research Communications, 2015. **468**(3): p. 419-427.
35. Bhatia, S., *Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications*, in *Natural polymer drug delivery systems*. 2016, Springer. p. 33-93.
36. Goldman, E.R., et al., *Conjugation of Luminescent Quantum Dots with Antibodies Using an Engineered Adaptor Protein To Provide New Reagents for Fluoroimmunoassays*. Analytical Chemistry, 2002. **74**(4): p. 841-847.
37. Goldman, E.R., et al., *Avidin: a natural bridge for quantum dot-antibody conjugates*. Journal of the American Chemical Society, 2002. **124**(22): p. 6378-6382.

38. Parak, W.J., et al., *Conjugation of DNA to silanized colloidal semiconductor nanocrystalline quantum dots*. Chemistry of Materials, 2002. **14**(5): p. 2113-2119.
39. Pathak, S., et al., *Hydroxylated quantum dots as luminescent probes for in situ hybridization*. Journal of the American Chemical Society, 2001. **123**(17): p. 4103-4104.
40. Zhang, H., D. Yee, and C. Wang, *Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives*. 2008.
41. Shao, D., et al., *Monitoring HSV-TK/ganciclovir cancer suicide gene therapy using CdTe/CdS core/shell quantum dots*. Biomaterials, 2012. **33**(17): p. 4336-4344.
42. Crooks, R.M., et al., *Dendrimer-Encapsulated Metal Nanoparticles: Synthesis, Characterization, and Applications to Catalysis*. Accounts of Chemical Research, 2001. **34**(3): p. 181-190.
43. Ovais, M., et al., *Role of plant phytochemicals and microbial enzymes in biosynthesis of metallic nanoparticles*. Applied Microbiology and Biotechnology, 2018. **102**(16): p. 6799-6814.
44. Panda, T. and K. Deepa, *Biosynthesis of gold nanoparticles*. Journal of nanoscience and nanotechnology, 2011. **11**(12): p. 10279-10294.
45. Singh, P., et al., *Biological Synthesis of Nanoparticles from Plants and Microorganisms*. Trends in Biotechnology, 2016. **34**(7): p. 588-599.
46. Jeevanandam, J., et al., *Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations*. Beilstein Journal of Nanotechnology, 2018. **9**: p. 1050-1074.
47. Schmidt, H., *Nanoparticles by chemical synthesis, processing to materials and innovative applications*. Applied Organometallic Chemistry, 2001. **15**(5): p. 331-343.
48. Ling, D., N. Lee, and T. Hyeon, *Chemical Synthesis and Assembly of Uniformly Sized Iron Oxide Nanoparticles for Medical Applications*. Accounts of Chemical Research, 2015. **48**(5): p. 1276-1285.
49. Herricks, T., J. Chen, and Y. Xia, *Polyol synthesis of platinum nanoparticles: control of morphology with sodium nitrate*. Nano Letters, 2004. **4**(12): p. 2367-2371.
50. Van Dong, P., et al., *Chemical synthesis and antibacterial activity of novel-shaped silver nanoparticles*. International Nano Letters, 2012. **2**(1): p. 1-9.
51. Chen, Y., et al., *Shape controlled growth of gold nanoparticles by a solution synthesis*. Chemical Communications, 2005(33): p. 4181-4183.
52. Strambeanu, N., L. Demetrovici, and D. Dragos, *Natural sources of nanoparticles*, in *Nanoparticles' Promises and Risks*. 2015, Springer. p. 9-19.
53. Kavitha, K., et al., *Plants as green source towards synthesis of nanoparticles*. Int Res J Biol Sci, 2013. **2**(6): p. 66-76.
54. Iravani, S., et al., *Synthesis of silver nanoparticles: chemical, physical and biological methods*. Research in pharmaceutical sciences, 2014. **9**(6): p. 385-406.
55. Raffi, M., et al., *Studies of the growth parameters for silver nanoparticle synthesis by inert gas condensation*. Journal of Materials Research, 2011. **22**(12): p. 3378-3384.
56. Lee, K.-M., S.-T. Park, and D.-J. Lee, *Nanogold synthesis by inert gas condensation for immuno-chemistry probes*. Journal of Alloys and Compounds, 2005. **390**(1): p. 297-300.
57. Ward, M., R. Brydson, and R. Cochrane. *Mn nanoparticles produced by inert gas condensation*. in *Journal of Physics: Conference Series*. 2006. IOP Publishing.
58. Wen, Y. and D. Xia, *Particle size prediction of magnesium nanoparticle produced by inert gas condensation method*. Journal of Nanoparticle Research, 2017. **20**(1): p. 4.

59. Gracia-Pinilla, M., et al., *Deposition of Size-Selected Cu Nanoparticles by Inert Gas Condensation*. Nanoscale Research Letters, 2009. **5**(1): p. 180.
60. Suryanarayana, C. and B. Prabhu, 2 - *Synthesis of Nanostructured Materials by Inert-Gas Condensation Methods*, in *Nanostructured Materials (Second Edition)*, C.C. Koch, Editor. 2007, William Andrew Publishing: Norwich, NY. p. 47-90.
61. Semaltianos, N.G., *Nanoparticles by Laser Ablation*. Critical Reviews in Solid State and Materials Sciences, 2010. **35**(2): p. 105-124.
62. Mafuné, F., et al., *Formation and Size Control of Silver Nanoparticles by Laser Ablation in Aqueous Solution*. The Journal of Physical Chemistry B, 2000. **104**(39): p. 9111-9117.
63. Song, K.C., et al., *Preparation of colloidal silver nanoparticles by chemical reduction method*. Korean Journal of Chemical Engineering, 2009. **26**(1): p. 153-155.
64. Leopold, N. and B. Lendl, *A New Method for Fast Preparation of Highly Surface-Enhanced Raman Scattering (SERS) Active Silver Colloids at Room Temperature by Reduction of Silver Nitrate with Hydroxylamine Hydrochloride*. The Journal of Physical Chemistry B, 2003. **107**(24): p. 5723-5727.
65. Caswell, K.K., C.M. Bender, and C.J. Murphy, *Seedless, Surfactantless Wet Chemical Synthesis of Silver Nanowires*. Nano Letters, 2003. **3**(5): p. 667-669.
66. Sun, Y., et al., *Polyol Synthesis of Uniform Silver Nanowires: A Plausible Growth Mechanism and the Supporting Evidence*. Nano Letters, 2003. **3**(7): p. 955-960.
67. Wang, H., et al., *Preparation of silver nanoparticles by chemical reduction method*. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2005. **256**(2): p. 111-115.
68. Khan, Z., et al., *Preparation and characterization of silver nanoparticles by chemical reduction method*. Colloids and Surfaces B: Biointerfaces, 2011. **82**(2): p. 513-517.
69. Sun, Y. and Y. Xia, *Shape-Controlled Synthesis of Gold and Silver Nanoparticles*. Science, 2002. **298**(5601): p. 2176-2179.
70. Im, S.H., et al., *Large-Scale Synthesis of Silver Nanocubes: The Role of HCl in Promoting Cube Perfection and Monodispersity*. Angewandte Chemie International Edition, 2005. **44**(14): p. 2154-2157.
71. Zhu, Y., et al., *Seed-mediated synthesis of silver with skeleton structures*. Materials Letters, 2004. **58**(6): p. 1121-1126.
72. Dang, T.M.D., et al., *Synthesis and optical properties of copper nanoparticles prepared by a chemical reduction method*. Advances in Natural Sciences: Nanoscience and Nanotechnology, 2011. **2**(1): p. 015009.
73. Huang, K.-C. and S.H. Ehrman, *Synthesis of Iron Nanoparticles via Chemical Reduction with Palladium Ion Seeds*. Langmuir, 2007. **23**(3): p. 1419-1426.
74. Wu, Z.G., M. Munoz, and O. Montero, *The synthesis of nickel nanoparticles by hydrazine reduction*. Advanced Powder Technology, 2010. **21**(2): p. 165-168.
75. Long, N.N., et al., *Synthesis and optical properties of colloidal gold nanoparticles*. Journal of Physics: Conference Series, 2009. **187**: p. 012026.
76. López-Quintela, M.A., *Synthesis of nanomaterials in microemulsions: formation mechanisms and growth control*. Current Opinion in Colloid & Interface Science, 2003. **8**(2): p. 137-144.
77. López-Quintela, M., et al., *Synthesis of nanoparticles in microemulsions*, in *Nanoscale materials*. 2004, Springer. p. 135-155.

78. Maillard, M., S. Giorgio, and M.-P. Pileni, *Tuning the Size of Silver Nanodisks with Similar Aspect Ratios: Synthesis and Optical Properties*. The Journal of Physical Chemistry B, 2003. **107**(11): p. 2466-2470.
79. Kitchens, C.L., M.C. McLeod, and C.B. Roberts, *Solvent Effects on the Growth and Steric Stabilization of Copper Metallic Nanoparticles in AOT Reverse Micelle Systems*. The Journal of Physical Chemistry B, 2003. **107**(41): p. 11331-11338.
80. Cheng, X., et al., *Synthesis of iron nanoparticles in water-in-oil microemulsions for liquid-phase Fischer–Tropsch synthesis in polyethylene glycol*. Catalysis Communications, 2011. **12**(6): p. 431-435.
81. Pal, A., et al., *Room temperature synthesis of platinum nanoparticles in water-in-oil microemulsion*. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2009. **337**(1): p. 205-207.
82. Fernandez, C.A. and C.M. Wai, *Continuous Tuning of Cadmium Sulfide and Zinc Sulfide Nanoparticle Size in a Water-in-Supercritical Carbon Dioxide Microemulsion*. Chemistry—A European Journal, 2007. **13**(20): p. 5838-5844.
83. Wang, C.-C., D.-H. Chen, and T.-C. Huang, *Synthesis of palladium nanoparticles in water-in-oil microemulsions*. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2001. **189**(1): p. 145-154.
84. Kumar, A., et al., *Controlled synthesis of size-tunable nickel and nickel oxide nanoparticles using water-in-oil microemulsions*. Advances in Natural Sciences: Nanoscience and Nanotechnology, 2013. **4**(2): p. 025009.
85. Rajapantulu, A. and R. Bandyopadhyaya, *Formation of Gold Nanoparticles in Water-in-Oil Microemulsions: Experiment, Mechanism, and Simulation*. Langmuir, 2021. **37**(22): p. 6623-6631.
86. Choi, S.-H., et al., *Interaction between the surface of the silver nanoparticles prepared by γ -irradiation and organic molecules containing thiol group*. Radiation Physics and Chemistry, 2003. **67**(3): p. 517-521.
87. Tsuji, T., T. Kakita, and M. Tsuji, *Preparation of nano-size particles of silver with femtosecond laser ablation in water*. Applied Surface Science, 2003. **206**(1): p. 314-320.
88. He, B., et al., *Synthesis of size controlled Ag nanoparticles*. Journal of Molecular Catalysis A: Chemical, 2004. **221**(1): p. 121-126.
89. Yin, H., et al., *Large-scale and size-controlled synthesis of silver nanoparticles under microwave irradiation*. Materials Chemistry and Physics, 2004. **83**(1): p. 66-70.
90. Yamamoto, T., et al., *Morphology-Control in Microwave-Assisted Synthesis of Silver Particles in Aqueous Solutions*. Bulletin of the Chemical Society of Japan, 2004. **77**(4): p. 757-761.
91. Liu, F.-K., et al., *Microwave-assisted synthesis of silver nanorods*. Journal of Materials Research, 2011. **19**(2): p. 469-473.
92. Mawaddah, M.O., et al. *Green synthesis of silver nanoparticles using photo-induced reduction method*. in *AIP Conference Proceedings*. 2018. AIP Publishing LLC.
93. Stamplecoskie, K.G. and J.C. Scaiano, *Light Emitting Diode Irradiation Can Control the Morphology and Optical Properties of Silver Nanoparticles*. Journal of the American Chemical Society, 2010. **132**(6): p. 1825-1827.
94. Shchukin, D.G., I.L. Radtchenko, and G.B. Sukhorukov, *Photoinduced Reduction of Silver inside Microscale Polyelectrolyte Capsules*. ChemPhysChem, 2003. **4**(10): p. 1101-1103.

95. Singaravelan, R. and S.B.S. Alwar, *Electrochemical synthesis, characterisation and phytogetic properties of silver nanoparticles*. Applied Nanoscience, 2015. **5**(8): p. 983-991.
96. Yin, B., et al., *Electrochemical Synthesis of Silver Nanoparticles under Protection of Poly(N-vinylpyrrolidone)*. The Journal of Physical Chemistry B, 2003. **107**(34): p. 8898-8904.
97. Ma, H., et al., *Synthesis of Silver and Gold Nanoparticles by a Novel Electrochemical Method*. ChemPhysChem, 2004. **5**(1): p. 68-75.
98. Sáez, V. and T.J. Mason, *Sonoelectrochemical synthesis of nanoparticles*. Molecules (Basel, Switzerland), 2009. **14**(10): p. 4284-4299.
99. Sardar, R., J.-W. Park, and J.S. Shumaker-Parry, *Polymer-Induced Synthesis of Stable Gold and Silver Nanoparticles and Subsequent Ligand Exchange in Water*. Langmuir, 2007. **23**(23): p. 11883-11889.
100. Yin, Y., et al., *Synthesis and characterization of stable aqueous dispersions of silver nanoparticles through the Tollens process*. Journal of Materials Chemistry, 2002. **12**(3): p. 522-527.
101. AbuDalo, M.A., et al., *Synthesis of silver nanoparticles using a modified Tollens' method in conjunction with phytochemicals and assessment of their antimicrobial activity*. PeerJ, 2019. **7**: p. e6413-e6413.
102. Fouda, A., et al., *Facile approach towards medical textiles via myco-synthesis of silver nanoparticles*. Der Pharma Chemica, 2017. **9**: p. 11-18.
103. Prabhu, S. and E.K. Poulose, *Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects*. International Nano Letters, 2012. **2**(1): p. 32.
104. John, M.S., et al., *Synthesis of bioactive silver nanoparticles by a Pseudomonas strain associated with the antarctic psychrophilic protozoon Euplotes focardii*. Marine drugs, 2020. **18**(1): p. 38.
105. Kalishwaralal, K., et al., *Extracellular biosynthesis of silver nanoparticles by the culture supernatant of Bacillus licheniformis*. Materials Letters, 2008. **62**(29): p. 4411-4413.
106. Elbeshehy, E.K.F., A.M. Elazzazy, and G. Aggelis, *Silver nanoparticles synthesis mediated by new isolates of Bacillus spp., nanoparticle characterization and their activity against Bean Yellow Mosaic Virus and human pathogens*. Frontiers in Microbiology, 2015. **6**.
107. Thomas, R., et al., *Antibacterial properties of silver nanoparticles synthesized by marine Ochrobactrum sp*. Brazilian Journal of Microbiology, 2014. **45**(4): p. 1221-1227.
108. Monowar, T., et al., *Silver Nanoparticles Synthesized by Using the Endophytic Bacterium Pantoea ananatis are Promising Antimicrobial Agents against Multidrug Resistant Bacteria*. Molecules, 2018. **23**(12): p. 3220.
109. Saravanan, M., et al., *Synthesis of silver nanoparticles from Bacillus brevis (NCIM 2533) and their antibacterial activity against pathogenic bacteria*. Microbial Pathogenesis, 2018. **116**: p. 221-226.
110. Iqtedar, M., et al., *Extracellular biosynthesis, characterization, optimization of silver nanoparticles (AgNPs) using Bacillus mojavensis BTCB15 and its antimicrobial activity against multidrug resistant pathogens*. Preparative Biochemistry & Biotechnology, 2019. **49**(2): p. 136-142.

111. Wypij, M., et al. *Actinobacterial-mediated synthesis of silver nanoparticles and their activity against pathogenic bacteria*. IET Nanobiotechnology, 2017. **11**, 336-342.
112. Manikprabhu, D., et al., *Sunlight mediated synthesis of silver nanoparticles by a novel actinobacterium (Sinomonas mesophila MPKL 26) and its antimicrobial activity against multi drug resistant Staphylococcus aureus*. Journal of Photochemistry and Photobiology B: Biology, 2016. **158**: p. 202-205.
113. Gan, L., et al., *Biosynthesis, characterization and antimicrobial activity of silver nanoparticles by a halotolerant Bacillus endophyticus SCU-L*. Preparative Biochemistry & Biotechnology, 2018. **48**(7): p. 582-588.
114. Shanthi, S., et al., *Biosynthesis of silver nanoparticles using a probiotic Bacillus licheniformis Dahb1 and their antibiofilm activity and toxicity effects in Ceriodaphnia cornuta*. Microbial Pathogenesis, 2016. **93**: p. 70-77.
115. Wang, C., et al., *Green synthesis of silver nanoparticles by Bacillus methylotrophicus, and their antimicrobial activity*. Artificial Cells, Nanomedicine, and Biotechnology, 2016. **44**(4): p. 1127-1132.
116. Malhotra, A., et al., *Biosynthesis of gold and silver nanoparticles using a novel marine strain of Stenotrophomonas*. Bioresource Technology, 2013. **142**: p. 727-731.
117. Srinath, B., K. Namratha, and K. Byrappa, *Eco-friendly synthesis of gold nanoparticles by Bacillus subtilis and their environmental applications*. Advanced Science Letters, 2018. **24**(8): p. 5942-5946.
118. Ahmed, E., et al., *Synthesis of ultra-small platinum, palladium and gold nanoparticles by Shewanella loihica PV-4 electrochemically active biofilms and their enhanced catalytic activities*. Journal of Saudi Chemical Society, 2018. **22**(8): p. 919-929.
119. Kaur, H., et al., *Marine microbe as nano-factories for copper biomineralization*. Biotechnology and Bioprocess Engineering, 2015. **20**(1): p. 51-57.
120. Lv, Q., et al., *Biosynthesis of copper nanoparticles using Shewanella loihica PV-4 with antibacterial activity: Novel approach and mechanisms investigation*. Journal of hazardous materials, 2018. **347**: p. 141-149.
121. Rauf, M.A., et al., *Biomimetically synthesized ZnO nanoparticles attain potent antibacterial activity against less susceptible S. aureus skin infection in experimental animals*. RSC advances, 2017. **7**(58): p. 36361-36373.
122. Jha, A.K., K. Prasad, and A. Kulkarni, *Synthesis of TiO₂ nanoparticles using microorganisms*. Colloids and Surfaces B: Biointerfaces, 2009. **71**(2): p. 226-229.
123. Fouda, A., et al., *Antimicrobial, Antioxidant and Larvicidal Activities of Spherical Silver Nanoparticles Synthesized by Endophytic Streptomyces spp.* Biological Trace Element Research, 2020. **195**(2): p. 707-724.
124. Manivasagan, P., et al., *Biosynthesis, Antimicrobial and Cytotoxic Effect of Silver Nanoparticles Using a Novel *Nocardia* sp. MBRC-1*. BioMed Research International, 2013. **2013**: p. 287638.
125. Buszewski, B., et al., *Antimicrobial activity of biosilver nanoparticles produced by a novel Streptacidiphilus durhamensis strain*. Journal of Microbiology, Immunology and Infection, 2018. **51**(1): p. 45-54.
126. Abd-Elnaby, H.M., et al., *Antibacterial and anticancer activity of extracellular synthesized silver nanoparticles from marine Streptomyces rochei MHM13*. The Egyptian Journal of Aquatic Research, 2016. **42**(3): p. 301-312.

127. Alani, F., M. Moo-Young, and W. Anderson, *Biosynthesis of silver nanoparticles by a new strain of Streptomyces sp. compared with Aspergillus fumigatus*. World Journal of Microbiology and Biotechnology, 2012. **28**(3): p. 1081-1086.
128. Sowani, H., et al., *Green synthesis of gold and silver nanoparticles by an actinomycete Gordonia amicalis HS-11: mechanistic aspects and biological application*. Process Biochemistry, 2016. **51**(3): p. 374-383.
129. Ahmad, A., et al., *Intracellular synthesis of gold nanoparticles by a novel alkalotolerant actinomycete, Rhodococcus species*. Nanotechnology, 2003. **14**(7): p. 824.
130. Manivasagan, P., et al., *Extracellular synthesis of gold nanoparticles by Nocardiopsis sp. and evaluation of its antimicrobial, antioxidant and cytotoxic activities*. Bioprocess and biosystems engineering, 2015. **38**(6): p. 1167-1177.
131. Hassan, S.E.-D., et al., *New approach for antimicrobial activity and bio-control of various pathogens by biosynthesized copper nanoparticles using endophytic actinomycetes*. Journal of Radiation Research and Applied Sciences, 2018. **11**(3): p. 262-270.
132. Hassan, S.E.-D., et al., *Endophytic actinomycetes Streptomyces spp mediated biosynthesis of copper oxide nanoparticles as a promising tool for biotechnological applications*. JBIC Journal of Biological Inorganic Chemistry, 2019. **24**(3): p. 377-393.
133. Balraj, B., et al., *Synthesis and characterization of zinc oxide nanoparticles using marine Streptomyces sp. with its investigations on anticancer and antibacterial activity*. Research on Chemical Intermediates, 2017. **43**(4): p. 2367-2376.
134. Mohamed, A.A., et al., *Fungal strain impacts the shape, bioactivity and multifunctional properties of green synthesized zinc oxide nanoparticles*. Biocatalysis and Agricultural Biotechnology, 2019. **19**: p. 101103.
135. Spagnoletti, F.N., et al., *Extracellular biosynthesis of bactericidal Ag/AgCl nanoparticles for crop protection using the fungus Macrophomina phaseolina*. Journal of Environmental Management, 2019. **231**: p. 457-466.
136. AbdelRahim, K., et al., *Extracellular biosynthesis of silver nanoparticles using Rhizopus stolonifer*. Saudi Journal of Biological Sciences, 2017. **24**(1): p. 208-216.
137. Jalal, M., et al., *Biosynthesis of Silver Nanoparticles from Oropharyngeal Candida glabrata Isolates and Their Antimicrobial Activity against Clinical Strains of Bacteria and Fungi*. Nanomaterials, 2018. **8**(8): p. 586.
138. Kobashigawa, J.M., et al., *Influence of strong bases on the synthesis of silver nanoparticles (AgNPs) using the ligninolytic fungi Trametes trogii*. Saudi Journal of Biological Sciences, 2019. **26**(7): p. 1331-1337.
139. Elamawi, R.M., R.E. Al-Harbi, and A.A. Hendi, *Biosynthesis and characterization of silver nanoparticles using Trichoderma longibrachiatum and their effect on phytopathogenic fungi*. Egyptian Journal of Biological Pest Control, 2018. **28**(1): p. 28.
140. Ahmed, A.-A., H. Hamzah, and M. Maarroof, *Analyzing formation of silver nanoparticles from the filamentous fungus Fusarium oxysporum and their antimicrobial activity*. Turkish Journal of Biology, 2018. **42**(1): p. 54-62.
141. Singh, P.S. and G.M. Vidyasagar, *Biosynthesis of antibacterial silver nano-particles from Aspergillus terreus*. World News of Natural Sciences, 2018(16): p. 109-116.
142. Joshi, C.G., et al., *Biogenic synthesis of gold nanoparticles by marine endophytic fungus-Cladosporium cladosporioides isolated from seaweed and evaluation of their antioxidant and antimicrobial properties*. Process Biochemistry, 2017. **63**: p. 137-144.

143. Kitching, M., et al., *Fungal surface protein mediated one-pot synthesis of stable and hemocompatible gold nanoparticles*. Enzyme and Microbial Technology, 2016. **95**: p. 76-84.
144. Yang, Z., et al., *Controllable biosynthesis and properties of gold nanoplates using yeast extract*. Nano-micro letters, 2017. **9**(1): p. 1-13.
145. Subramaniyan, S.A., et al., *One-pot facile synthesis of Pt nanoparticles using cultural filtrate of microgravity simulated grown *P. chrysogenum* and their activity on bacteria and cancer cells*. Journal of Nanoscience and Nanotechnology, 2018. **18**(5): p. 3110-3125.
146. Kalpana, V., et al., *Biosynthesis of zinc oxide nanoparticles using culture filtrates of *Aspergillus niger*: Antimicrobial textiles and dye degradation studies*. OpenNano, 2018. **3**: p. 48-55.
147. Moghaddam, A.B., et al., *Biosynthesis of ZnO nanoparticles by a new *Pichia kudriavzevii* yeast strain and evaluation of their antimicrobial and antioxidant activities*. Molecules, 2017. **22**(6): p. 872.
148. Sarkar, J., et al., *An eco-friendly route of γ -Fe₂O₃ nanoparticles formation and investigation of the mechanical properties of the HPMC- γ -Fe₂O₃ nanocomposites*. Bioprocess and biosystems engineering, 2017. **40**(3): p. 351-359.
149. Sriramulu, M. and S. Sumathi, *Biosynthesis of palladium nanoparticles using *Saccharomyces cerevisiae* extract and its photocatalytic degradation behaviour*. Advances in Natural Sciences: Nanoscience and Nanotechnology, 2018. **9**(2): p. 025018.
150. Fatima, R., et al., *Biosynthesis of silver nanoparticles using red algae *Portieria hornemannii* and its antibacterial activity against fish pathogens*. Microbial Pathogenesis, 2020. **138**: p. 103780.
151. Bhuyar, P., et al., *Synthesis of silver nanoparticles using marine macroalgae *Padina sp.* and its antibacterial activity towards pathogenic bacteria*. Beni-Suef University Journal of Basic and Applied Sciences, 2020. **9**(1): p. 3.
152. Pugazhendhi, A., et al., *Synthesis and characterization of silver nanoparticles using *Gelidium amansii* and its antimicrobial property against various pathogenic bacteria*. Microbial Pathogenesis, 2018. **114**: p. 41-45.
153. Love, A.J., et al., *The use of tobacco mosaic virus and cowpea mosaic virus for the production of novel metal nanomaterials*. Virology, 2014. **449**: p. 133-139.
154. Gardea-Torresdey, J.L., et al., *Alfalfa Sprouts: A Natural Source for the Synthesis of Silver Nanoparticles*. Langmuir, 2003. **19**(4): p. 1357-1361.
155. Ahn, E.-Y., H. Jin, and Y. Park, *Assessing the antioxidant, cytotoxic, apoptotic and wound healing properties of silver nanoparticles green-synthesized by plant extracts*. Materials Science and Engineering: C, 2019. **101**: p. 204-216.
156. Parthiban, E., et al., *Green synthesis of silver-nanoparticles from *Annona reticulata* leaves aqueous extract and its mosquito larvicidal and anti-microbial activity on human pathogens*. Biotechnology Reports, 2019. **21**: p. e00297.
157. Rolim, W.R., et al., *Green tea extract mediated biogenic synthesis of silver nanoparticles: Characterization, cytotoxicity evaluation and antibacterial activity*. Applied Surface Science, 2019. **463**: p. 66-74.
158. Razavi, R., et al., *Biosynthesis of metallic nanoparticles using mulberry fruit (*Morus alba L.*) extract for the preparation of antimicrobial nanocellulose film*. Applied Nanoscience, 2020. **10**(2): p. 465-476.

159. Sreekanth, T., et al., *Ultra-sonication-assisted silver nanoparticles using Panax ginseng root extract and their anti-cancer and antiviral activities*. Journal of Photochemistry and Photobiology B: Biology, 2018. **188**: p. 6-11.
160. Chahardoli, A., et al., *Green approach for synthesis of gold nanoparticles from Nigella arvensis leaf extract and evaluation of their antibacterial, antioxidant, cytotoxicity and catalytic activities*. Artificial cells, nanomedicine, and biotechnology, 2018. **46**(3): p. 579-588.
161. Ahmad, A., et al., *Synthesis of phytochemicals-stabilized gold nanoparticles and their biological activities against bacteria and Leishmania*. Microbial pathogenesis, 2017. **110**: p. 304-312.
162. Rajesh, K., et al., *Assisted green synthesis of copper nanoparticles using Syzygium aromaticum bud extract: Physical, optical and antimicrobial properties*. Optik, 2018. **154**: p. 593-600.
163. Katata-Seru, L., et al., *Green synthesis of iron nanoparticles using Moringa oleifera extracts and their applications: removal of nitrate from water and antibacterial activity against Escherichia coli*. Journal of Molecular Liquids, 2018. **256**: p. 296-304.
164. Ramalingam, V., et al., *Green fabrication of iron oxide nanoparticles using grey mangrove Avicennia marina for antibiofilm activity and in vitro toxicity*. Surfaces and Interfaces, 2019. **15**: p. 70-77.
165. Fahimmunisha, B.A., et al., *Green fabrication, characterization and antibacterial potential of zinc oxide nanoparticles using Aloe socotrina leaf extract: A novel drug delivery approach*. Journal of Drug Delivery Science and Technology, 2020. **55**: p. 101465.
166. El-Sayed, M.A., *Some Interesting Properties of Metals Confined in Time and Nanometer Space of Different Shapes*. Accounts of Chemical Research, 2001. **34**(4): p. 257-264.
167. Wilczewska, A.Z., et al., *Nanoparticles as drug delivery systems*. Pharmacological reports, 2012. **64**(5): p. 1020-1037.
168. Sharma, P., et al., *Nanoparticles for bioimaging*. Advances in Colloid and Interface Science, 2006. **123-126**: p. 471-485.
169. Selvan, S.T., et al., *Functional and Multifunctional Nanoparticles for Bioimaging and Biosensing*. Langmuir, 2010. **26**(14): p. 11631-11641.
170. Holzinger, M., A. Le Goff, and S. Cosnier, *Nanomaterials for biosensing applications: a review*. Frontiers in Chemistry, 2014. **2**.
171. Li, Y., et al., *Copper sulfide nanoparticles for photothermal ablation of tumor cells*. Nanomedicine, 2010. **5**(8): p. 1161-1171.
172. Cherukuri, P., E.S. Glazer, and S.A. Curley, *Targeted hyperthermia using metal nanoparticles*. Advanced drug delivery reviews, 2010. **62**(3): p. 339-345.
173. Bernsen, M.R., et al., *Nanoparticles and clinically applicable cell tracking*. The British journal of radiology, 2015. **88**(1054): p. 20150375.
174. Liu, C. and N. Zhang, *Nanoparticles in gene therapy: principles, prospects, and challenges*. Progress in molecular biology and translational science, 2011. **104**: p. 509-562.
175. Thanh, N.T.K. and L.A.W. Green, *Functionalisation of nanoparticles for biomedical applications*. Nano Today, 2010. **5**(3): p. 213-230.
176. Liang, H., et al., *Controlled Synthesis of Uniform Silver Nanospheres*. The Journal of Physical Chemistry C, 2010. **114**(16): p. 7427-7431.

177. Hu, J.-Q., et al., *A Simple and Effective Route for the Synthesis of Crystalline Silver Nanorods and Nanowires*. *Advanced Functional Materials*, 2004. **14**(2): p. 183-189.
178. Pastoriza-Santos, I. and L.M. Liz-Marzán, *Synthesis of Silver Nanoprisms in DMF*. *Nano Letters*, 2002. **2**(8): p. 903-905.
179. Flores, J.C., et al., *Variations in morphologies of silver nanoshells on silica spheres*. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 2008. **330**(1): p. 86-90.
180. Zhou, S., et al., *Facile Synthesis of Silver Nanocubes with Sharp Corners and Edges in an Aqueous Solution*. *ACS Nano*, 2016. **10**(11): p. 9861-9870.
181. Chen, S., et al., *Morphology effects on the optical properties of silver nanoparticles*. *Journal of Nanoscience and Nanotechnology*, 2004. **4**(3): p. 254-259.
182. Wang, Y., et al., *Synthesis of Ag nanocubes 18-32 nm in edge length: the effects of polyol on reduction kinetics, size control, and reproducibility*. *J Am Chem Soc*, 2013. **135**(5): p. 1941-51.
183. Mazzucco, S., et al., *Ultralocal Modification of Surface Plasmons Properties in Silver Nanocubes*. *Nano Letters*, 2012. **12**(3): p. 1288-1294.
184. Das, R. and S. Sarkar, *Optical properties of silver nano-cubes*. *Optical Materials*, 2015. **48**: p. 203-208.
185. Han, H.J., et al., *Highly reproducible polyol synthesis for silver nanocubes*. *Journal of Crystal Growth*, 2017. **469**: p. 48-53.
186. Siekkinen, A.R., et al., *Rapid synthesis of small silver nanocubes by mediating polyol reduction with a trace amount of sodium sulfide or sodium hydrosulfide*. *Chem Phys Lett*, 2006. **432**(4-6): p. 491-496.
187. Qi, S., et al., *Synthesis of silver nanocubes with controlled size using water-soluble poly(amic acid) salt as the intermediate via a novel ion-exchange self-assembly technique*. *Nanoscale*, 2013. **5**(24): p. 12132-12135.
188. Panfilova, E.V., et al., *Study of polyol synthesis reaction parameters controlling high yield of silver nanocubes*. *Colloid Journal*, 2012. **74**(1): p. 99-109.
189. Yu, D. and V.W. Yam, *Hydrothermal-induced assembly of colloidal silver spheres into various nanoparticles on the basis of HTAB-modified silver mirror reaction*. *J Phys Chem B*, 2005. **109**(12): p. 5497-503.
190. Gudikandula, K., P. Vadapally, and M.A.S. Charya, *Biogenic synthesis of silver nanoparticles from white rot fungi: Their characterization and antibacterial studies*. *OpenNano*, 2017. **2**: p. 64-78.
191. Mokhena, T.C. and A.S. Luyt, *Electrospun alginate nanofibres impregnated with silver nanoparticles: Preparation, morphology and antibacterial properties*. *Carbohydr Polym*, 2017. **165**: p. 304-312.
192. López-Esparza, J., et al., *Antimicrobial Activity of Silver Nanoparticles in Polycaprolactone Nanofibers against Gram-Positive and Gram-Negative Bacteria*. *Industrial & Engineering Chemistry Research*, 2016. **55**(49): p. 12532-12538.
193. Izak-Nau, E., et al., *Impact of storage conditions and storage time on silver nanoparticles' physicochemical properties and implications for their biological effects*. *Rsc Advances*, 2015. **5**(102): p. 84172-84185.
194. Dong, Y., et al., *Antibacterial activity of silver nanoparticles of different particle size against *Vibrio Natriegens**. *PLOS ONE*, 2019. **14**(9): p. e0222322.

195. Hong, X., et al., *Shape effect on the antibacterial activity of silver nanoparticles synthesized via a microwave-assisted method*. Environ Sci Pollut Res Int, 2016. **23**(5): p. 4489-97.
196. Panáček, A., et al., *Strong and Nonspecific Synergistic Antibacterial Efficiency of Antibiotics Combined with Silver Nanoparticles at Very Low Concentrations Showing No Cytotoxic Effect*. Molecules, 2016. **21**(1): p. 26.
197. Zhou, Y., et al., *PLLA microcapsules combined with silver nanoparticles and chlorhexidine acetate showing improved antibacterial effect*. Materials Science and Engineering: C, 2017. **78**: p. 349-353.
198. Amooaghaie, R., M.R. Saeri, and M. Azizi, *Synthesis, characterization and biocompatibility of silver nanoparticles synthesized from Nigella sativa leaf extract in comparison with chemical silver nanoparticles*. Ecotoxicology and Environmental Safety, 2015. **120**: p. 400-408.
199. AshaRani, P.V., et al., *Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells*. ACS Nano, 2009. **3**(2): p. 279-290.
200. AshaRani, P.V., et al., *Differential regulation of intracellular factors mediating cell cycle, DNA repair and inflammation following exposure to silver nanoparticles in human cells*. Genome Integrity, 2012. **3**(1): p. 2.
201. Tian, J., et al., *Topical delivery of silver nanoparticles promotes wound healing*. ChemMedChem, 2007. **2**(1): p. 129-36.
202. Durán, N., et al., *Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity*. Nanomedicine: Nanotechnology, Biology and Medicine, 2016. **12**(3): p. 789-799.
203. Wu, K., et al., *Antimicrobial activity and cytocompatibility of silver nanoparticles coated catheters via a biomimetic surface functionalization strategy*. International journal of nanomedicine, 2015. **10**: p. 7241-7252.
204. Mala, R., et al., *Foley catheters functionalised with a synergistic combination of antibiotics and silver nanoparticles resist biofilm formation*. IET nanobiotechnology, 2017. **11**(5): p. 612-620.
205. Kaur, P. and R. Luthra, *Silver nanoparticles in dentistry: An emerging trend*. SRM Journal of Research in Dental Sciences, 2016. **7**(3): p. 162-165.
206. Kumar, S.S.D., et al., *Recent advances on silver nanoparticle and biopolymer-based biomaterials for wound healing applications*. International Journal of Biological Macromolecules, 2018. **115**: p. 165-175.
207. Lu, H., et al., *Biomaterials with Antibacterial and Osteoinductive Properties to Repair Infected Bone Defects*. International Journal of Molecular Sciences, 2016. **17**(3): p. 334.
208. Adeyemi, O.S. and F.A. Sulaiman, *Evaluation of metal nanoparticles for drug delivery systems*. Journal of biomedical research, 2015. **29**(2): p. 145-149.
209. Liu, Z., et al., *Polysaccharides-based nanoparticles as drug delivery systems*. Advanced Drug Delivery Reviews, 2008. **60**(15): p. 1650-1662.
210. Manjunath, K., J.S. Reddy, and V. Venkateswarlu, *Solid lipid nanoparticles as drug delivery systems*. Methods Find Exp Clin Pharmacol, 2005. **27**(2): p. 127-144.
211. Hong, S., et al., *Protein-Based Nanoparticles as Drug Delivery Systems*. Pharmaceutics, 2020. **12**(7): p. 604.
212. Jahangirian, H., et al., *A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine*. International journal of nanomedicine, 2017. **12**: p. 2957-2978.

213. Jiang, Q., et al., *Evaluation of local anesthetic effects of Lidocaine-Ibuprofen ionic liquid stabilized silver nanoparticles in Male Swiss mice*. Journal of Photochemistry and Photobiology B: Biology, 2018. **178**: p. 367-370.
214. Karthik, C.S., et al., *Synthesis of novel benzodioxane midst piperazine moiety decorated chitosan silver nanoparticle against biohazard pathogens and as potential anti-inflammatory candidate: A molecular docking studies*. International Journal of Biological Macromolecules, 2018. **108**: p. 489-502.
215. Soni, N. and R.C. Dhiman, *Phytochemical, Anti-oxidant, Larvicidal, and Antimicrobial Activities of Castor (Ricinus communis) Synthesized Silver Nanoparticles*. Chinese Herbal Medicines, 2017. **9**(3): p. 289-294.
216. Selvan, D.A., et al., *Garlic, green tea and turmeric extracts-mediated green synthesis of silver nanoparticles: Phytochemical, antioxidant and in vitro cytotoxicity studies*. Journal of Photochemistry and Photobiology B: Biology, 2018. **180**: p. 243-252.
217. Al-Obaidi, H., R. Kalgudi, and M.G. Zariwala, *Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa*. European Journal of Pharmaceutics and Biopharmaceutics, 2018. **128**: p. 27-35.
218. Kaur, A., D. Goyal, and R. Kumar, *Surfactant mediated interaction of vancomycin with silver nanoparticles*. Applied Surface Science, 2018. **449**: p. 23-30.
219. Muhammad, Z., et al., *PEG capped methotrexate silver nanoparticles for efficient anticancer activity and biocompatibility*. European Journal of Pharmaceutical Sciences, 2016. **91**: p. 251-255.
220. Petrov, P.D., et al., *Multifunctional block copolymer nanocarriers for co-delivery of silver nanoparticles and curcumin: Synthesis and enhanced efficacy against tumor cells*. European Polymer Journal, 2016. **81**: p. 24-33.
221. Jhang, W.-L., M.-S. Huang, and S.-W. Hsu, *Unsymmetrical Heterogeneous Au-Ag Nanocrystals as Catalysts, Sensors, and Drug Carriers*. ACS Applied Nano Materials, 2021. **4**(10): p. 10011-10017.
222. Baker, C., et al., *Synthesis and antibacterial properties of silver nanoparticles*. Journal of nanoscience and nanotechnology, 2005. **5**(2): p. 244-249.
223. Galdiero, S., et al., *Silver Nanoparticles as Potential Antiviral Agents*. Molecules, 2011. **16**(10): p. 8894-8918.
224. Panáček, A., et al., *Antifungal activity of silver nanoparticles against Candida spp*. Biomaterials, 2009. **30**(31): p. 6333-6340.
225. Gurunathan, S., et al., *Antiangiogenic properties of silver nanoparticles*. Biomaterials, 2009. **30**(31): p. 6341-6350.
226. Hebeish, A., et al., *Antimicrobial wound dressing and anti-inflammatory efficacy of silver nanoparticles*. International Journal of Biological Macromolecules, 2014. **65**: p. 509-515.
227. Shrivastava, S., et al., *Characterization of Antiplatelet Properties of Silver Nanoparticles*. ACS Nano, 2009. **3**(6): p. 1357-1364.
228. Ding, J., et al., *One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells*. Pharmaceutics, 2019. **11**(3): p. 123.
229. Palai, P.K., et al., *Green synthesized amino-PEGylated silver decorated graphene nanoplatfom as a tumor-targeted controlled drug delivery system*. SN Applied Sciences, 2019. **1**(3): p. 269.

230. Shi, J., et al., *Endothelial cell injury and dysfunction induced by silver nanoparticles through oxidative stress via IKK/NF- κ B pathways*. *Biomaterials*, 2014. **35**(24): p. 6657-6666.
231. Asharani, P.V., M.P. Hande, and S. Valiyaveetil, *Anti-proliferative activity of silver nanoparticles*. *BMC Cell Biology*, 2009. **10**(1): p. 65.
232. Thompson, E.A., et al., *Differential response of MCF7, MDA-MB-231, and MCF 10A cells to hyperthermia, silver nanoparticles and silver nanoparticle-induced photothermal therapy*. *International Journal of Hyperthermia*, 2014. **30**(5): p. 312-323.
233. Shandiz, S.A.S., et al., *Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells*. *Artificial Cells, Nanomedicine, and Biotechnology*, 2017. **45**(6): p. 1082-1091.
234. Li, Y., et al., *Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis*. *International journal of nanomedicine*, 2016. **11**: p. 6693-6702.
235. Wang, Y., B.B. Newell, and J. Irudayaraj, *Folic acid protected silver nanocarriers for targeted drug delivery*. *Journal of Biomedical Nanotechnology*, 2012. **8**(5): p. 751-759.
236. Behnam, M.A., et al., *Novel Combination of Silver Nanoparticles and Carbon Nanotubes for Plasmonic Photo Thermal Therapy in Melanoma Cancer Model*. *Advanced pharmaceutical bulletin*, 2018. **8**(1): p. 49-55.
237. Zhang, L., et al., *Refractive index dependent real-time plasmonic nanoprobe on a single silver nanocube for ultrasensitive detection of the lung cancer-associated miRNAs*. *Chemical Communications*, 2015. **51**(2): p. 294-297.
238. Liu, Y., et al., *Plasmonic Ag nanocube enhanced SERS biosensor for sensitive detection of oral cancer DNA based on nicking endonuclease signal amplification and heated electrode*. *Sensors and Actuators B: Chemical*, 2021. **338**: p. 129854.
239. Chen, J., et al., *Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells*. *Nano Lett*, 2007. **7**(5): p. 1318-22.
240. Vines, J.B., et al., *Gold Nanoparticles for Photothermal Cancer Therapy*. *Frontiers in Chemistry*, 2019. **7**.
241. Sun, M., et al., *Cancer Cell-Erythrocyte Hybrid Membrane Coated Gold Nanocages for Near Infrared Light-Activated Photothermal/Radio/Chemotherapy of Breast Cancer*. *International journal of nanomedicine*, 2020. **15**: p. 6749-6760.
242. Choi, H.S. and J.V. Frangioni, *Nanoparticles for biomedical imaging: fundamentals of clinical translation*. *Molecular imaging*, 2010. **9**(6): p. 7290.2010. 00031.
243. Tan, P., et al., *Silver nanoparticle in biosensor and bioimaging: Clinical perspectives*. *Biotechnology and Applied Biochemistry*, 2021. **68**(6): p. 1236-1242.
244. Arendowski, A., et al., *Laser desorption/ionization MS imaging of cancer kidney tissue on silver nanoparticle-enhanced target*. *Bioanalysis*, 2018. **10**(2): p. 83-94.
245. Paul, S., et al., *Surface plasmon resonance imaging detection of silver nanoparticle-tagged immunoglobulin*. *Journal of the Royal Society Interface*, 2011. **8**(61): p. 1204-1211.
246. Chen, L.Q., et al., *Aptamer-Based Silver Nanoparticles Used for Intracellular Protein Imaging and Single Nanoparticle Spectral Analysis*. *The Journal of Physical Chemistry B*, 2010. **114**(10): p. 3655-3659.
247. Zhao, L.-J., et al., *Sensitive detection of protein biomarkers using silver nanoparticles enhanced immunofluorescence assay*. *Theranostics*, 2017. **7**(4): p. 876.

248. Ren, X., et al., *Using silver nanoparticle to enhance current response of biosensor*. Biosensors and Bioelectronics, 2005. **21**(3): p. 433-437.
249. Dadhich, B.K., et al., *Femtosecond-Laser-Induced Saturable Absorption and Optical Limiting of Hollow Silver Nanocubes: Implications for Optical Switching and Bioimaging*. ACS Applied Nano Materials, 2020. **3**(11): p. 11620-11629.
250. Skrabalak, S.E., et al., *Facile synthesis of Ag nanocubes and Au nanocages*. Nature Protocols, 2007. **2**(9): p. 2182-2190.
251. Bottomley, A., D. Prezgot, and A. Ianoul, *Plasmonic properties of silver nanocube monolayers on high refractive index substrates*. Applied Physics A, 2012. **109**(4): p. 869-872.
252. Biemer, J.J., *Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method*. Annals of Clinical & Laboratory Science, 1973. **3**(2): p. 135-140.
253. Shimada, K., et al., *Antioxidative properties of xanthan on the autoxidation of soybean oil in cyclodextrin emulsion*. Journal of Agricultural and Food Chemistry, 1992. **40**(6): p. 945-948.
254. Golubeva, O.Y., et al., *Study of antimicrobial and hemolytic activities of silver nanoparticles prepared by chemical reduction*. Glass Physics and Chemistry, 2010. **36**(5): p. 628-634.
255. Chen, L.Q., et al., *Nanotoxicity of Silver Nanoparticles to Red Blood Cells: Size Dependent Adsorption, Uptake, and Hemolytic Activity*. Chemical Research in Toxicology, 2015. **28**(3): p. 501-509.
256. Shahzadi, T., et al., *Synthesis of Eco-friendly Cobalt Nanoparticles Using Celosia argentea Plant Extract and Their Efficacy Studies as Antioxidant, Antibacterial, Hemolytic and Catalytical Agent*. Arabian Journal for Science and Engineering, 2019. **44**(7): p. 6435-6444.
257. Rubab, K., et al., *Synthesis, pharmacological screening and computational analysis of some 2-(1H-Indol-3-yl)-N'-[(un) substituted phenylmethylidene] acetohydrazides and 2-(1H-Indol-3-yl)-N'-[(un) substituted benzoyl/2-thienylcarbonyl] acetohydrazides*. Pakistan journal of pharmaceutical sciences, 2017. **30**(4): p. 1263-1275.
258. Nadworny, P.L., et al., *Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model*. Nanomedicine: Nanotechnology, Biology and Medicine, 2008. **4**(3): p. 241-251.
259. David, L., et al., *Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry fruits extract*. Colloids and Surfaces B: Biointerfaces, 2014. **122**: p. 767-777.
260. Aafreen, M.M., et al., *Anti-inflammatory activity of silver nanoparticles prepared from ginger oil—An in vitro approach*. Indian Journal of Public Health Research & Development, 2019. **10**: p. 145.
261. Williams, L., et al., *The in vitro anti-denaturation effects induced by natural products and non-steroidal compounds in heat treated (immunogenic) bovine serum albumin is proposed as a screening assay for the detection of anti-inflammatory compounds, without the use of animals, in the early stages of the drug discovery process*. West Indian Medical Journal, 2008. **57**(4).
262. Parsek, M.R. and P.K. Singh, *Bacterial biofilms: an emerging link to disease pathogenesis*. Annu Rev Microbiol, 2003. **57**: p. 677-701.

263. Markowska, K., A.M. Grudniak, and K.I. Wolska, *Silver nanoparticles as an alternative strategy against bacterial biofilms*. Acta Biochimica Polonica, 2013. **60**(4).
264. Agrawal, N., et al., *Nano-cubes over nano-spheres: shape dependent study of silver nanomaterial for biological applications*. Bulletin of Materials Science, 2021. **44**(3): p. 191.
265. Shahid, S.A., et al., *Laser-assisted synthesis of MnO. 50ZnO. 50Fe2O4 nanomaterial: Characterization and in vitro inhibition activity towards Bacillus subtilis biofilm*. Journal of Nanomaterials, 2015. **2015**.
266. Anjum, F., et al., *Exploration of nutraceutical potential of herbal oil formulated from parasitic plant*. African Journal of Traditional, Complementary and Alternative Medicines, 2014. **11**(1): p. 78-86.
267. Qasim, N., et al., *Therapeutic Potential of Selected Varieties of Phoenix Dactylifera L. Against Microbial Biofilm and Free Radical Damage to DNA*. Dose-Response, 2020. **18**(4): p. 1559325820962609.
268. Xia, Y., et al., *Shape-Controlled Synthesis of Metal Nanocrystals: Simple Chemistry Meets Complex Physics?* Angewandte Chemie International Edition, 2009. **48**(1): p. 60-103.
269. Chernousova, S. and M. Epple, *Silver as antibacterial agent: ion, nanoparticle, and metal*. Angew Chem Int Ed Engl, 2013. **52**(6): p. 1636-53.
270. Marambio-Jones, C. and E.M.V. Hoek, *A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment*. Journal of Nanoparticle Research, 2010. **12**(5): p. 1531-1551.
271. Martínez-Castañón, G.A., et al., *Synthesis and antibacterial activity of silver nanoparticles with different sizes*. Journal of Nanoparticle Research, 2008. **10**(8): p. 1343-1348.
272. Raza, M.A., et al., *Size- and Shape-Dependent Antibacterial Studies of Silver Nanoparticles Synthesized by Wet Chemical Routes*. Nanomaterials, 2016. **6**(4): p. 74.
273. Sotiriou, G.A. and S.E. Pratsinis, *Antibacterial Activity of Nanosilver Ions and Particles*. Environmental Science & Technology, 2010. **44**(14): p. 5649-5654.
274. Kvítek, L., et al., *Effect of Surfactants and Polymers on Stability and Antibacterial Activity of Silver Nanoparticles (NPs)*. The Journal of Physical Chemistry C, 2008. **112**(15): p. 5825-5834.
275. Kirtiwar, S., S. Gharpure, and A. Balaprasad, *Effect of nutrient media on antibacterial activity of silver nanoparticles synthesized using Neolamarckia cadamba*. Journal of Nanoscience and Nanotechnology, 2019. **19**(4): p. 1923-1933.
276. Helmlinger, J., et al., *Silver nanoparticles with different size and shape: equal cytotoxicity, but different antibacterial effects*. RSC Advances, 2016. **6**(22): p. 18490-18501.
277. Hu, G., et al., *Antibacterial activity of silver nanoparticles with different morphologies as well as their possible antibacterial mechanism*. Applied Physics A, 2016. **122**(10): p. 874.
278. Korshed, P., et al., *Effect of Storage Conditions on the Long-Term Stability of Bactericidal Effects for Laser Generated Silver Nanoparticles*. Nanomaterials, 2018. **8**(4): p. 218.
279. Gauthami, M., et al., *Synthesis of silver nanoparticles using Cinnamomum zeylanicum bark extract and its antioxidant activity*. Nanoscience & Nanotechnology-Asia, 2015. **5**(1): p. 2-7.
280. Mitiku, A.A. and B. Yilma, *Antibacterial and antioxidant activity of silver nanoparticles synthesized using aqueous extract of Moringa stenopetala leaves*. African Journal of Biotechnology, 2017. **16**(32): p. 1705-1716.

281. Sreelekha, E., et al., *A Comparative Study on the Synthesis, Characterization, and Antioxidant Activity of Green and Chemically Synthesized Silver Nanoparticles*. *BioNanoScience*, 2021. **11**(2): p. 489-496.
282. Mousavi-Khattat, M., M. Keyhanfar, and A. Razmjou, *A comparative study of stability, antioxidant, DNA cleavage and antibacterial activities of green and chemically synthesized silver nanoparticles*. *Artificial Cells, Nanomedicine, and Biotechnology*, 2018. **46**(sup3): p. S1022-S1031.
283. Liao, C., Y. Li, and S.C. Tjong, *Bactericidal and Cytotoxic Properties of Silver Nanoparticles*. *International Journal of Molecular Sciences*, 2019. **20**(2): p. 449.
284. Wilkinson, L.J., R.J. White, and J.K. Chipman, *Silver and nanoparticles of silver in wound dressings: a review of efficacy and safety*. *Journal of Wound Care*, 2011. **20**(11): p. 543-549.
285. Nešporová, K., et al., *Effects of wound dressings containing silver on skin and immune cells*. *Scientific Reports*, 2020. **10**(1): p. 15216.
286. Kassinger, S.J. and M.L. van Hoek, *Biofilm architecture: An emerging synthetic biology target*. *Synth Syst Biotechnol*, 2020. **5**(1): p. 1-10.
287. Flemming, H.C., et al., *Biofilms: an emergent form of bacterial life*. *Nat Rev Microbiol*, 2016. **14**(9): p. 563-75.
288. Donlan, R.M., *Biofilm Formation: A Clinically Relevant Microbiological Process*. *Clinical Infectious Diseases*, 2001. **33**(8): p. 1387-1392.
289. Hall-Stoodley, L., et al., *Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media*. *Jama*, 2006. **296**(2): p. 202-211.
290. Elgharably, H., et al. *Current hypotheses in cardiac surgery: biofilm in infective endocarditis*. in *Seminars in thoracic and cardiovascular surgery*. 2016. Elsevier.
291. Kao, W., R.A. Chole, and M.A. Ogden, *Evidence of a microbial etiology for sialoliths*. *The Laryngoscope*, 2020. **130**(1): p. 69-74.
292. Bjarnsholt, T., *The role of bacterial biofilms in chronic infections*. *Apmis*, 2013. **121**: p. 1-58.
293. Verstraelen, H. and A. Swidsinski, *The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment: 2018 update*. *Current opinion in infectious diseases*, 2019. **32**(1): p. 38-42.
294. Høiby, N., O. Ciofu, and T. Bjarnsholt, *Pseudomonas aeruginosa biofilms in cystic fibrosis*. *Future microbiology*, 2010. **5**(11): p. 1663-1674.
295. Anderson, G.G., et al., *Intracellular bacterial biofilm-like pods in urinary tract infections*. *Science*, 2003. **301**(5629): p. 105-107.
296. Li, S., et al., *Bacterial biofilms in colorectal cancer initiation and progression*. *Trends in molecular medicine*, 2017. **23**(1): p. 18-30.
297. Koo, H., et al., *Targeting microbial biofilms: current and prospective therapeutic strategies*. *Nature Reviews Microbiology*, 2017. **15**(12): p. 740-755.
298. Sharahi, J.Y., et al., *Advanced strategies for combating bacterial biofilms*. *Journal of Cellular Physiology*, 2019. **234**(9): p. 14689-14708.
299. Roy, R., et al., *Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action*. *Virulence*, 2018. **9**(1): p. 522-554.
300. Wang, L.-S., A. Gupta, and V.M. Rotello, *Nanomaterials for the treatment of bacterial biofilms*. *ACS infectious diseases*, 2016. **2**(1): p. 3-4.

REFERENCES

301. Qayyum, S. and A.U. Khan, *Nanoparticles vs. biofilms: a battle against another paradigm of antibiotic resistance*. MedChemComm, 2016. **7**(8): p. 1479-1498.
302. Pinto, R.M., et al., *Impact of nanosystems in Staphylococcus aureus biofilms treatment*. FEMS microbiology reviews, 2019. **43**(6): p. 622-641.
303. Karygianni, L., et al., *Biofilm Matrixome: Extracellular Components in Structured Microbial Communities*. Trends Microbiol, 2020. **28**(8): p. 668-681.
304. Chatzimitakos, T.G. and C.D. Stalikas, *Qualitative Alterations of Bacterial Metabolome after Exposure to Metal Nanoparticles with Bactericidal Properties: A Comprehensive Workflow Based on (1)H NMR, UHPLC-HRMS, and Metabolic Databases*. J Proteome Res, 2016. **15**(9): p. 3322-30.
305. Zhao, L. and M.A. Ashraf, *Influence of Silver-hydroxyapatite Nanocomposite Coating on Biofilm Formation of Joint Prosthesis and Its Mechanism*. West Indian Med J, 2015. **64**(5): p. 506-513.
306. Sharma, V.K., R.A. Yngard, and Y. Lin, *Silver nanoparticles: Green synthesis and their antimicrobial activities*. Advances in Colloid and Interface Science, 2009. **145**(1): p. 83-96.
307. Hwang, E.T., et al., *Analysis of the Toxic Mode of Action of Silver Nanoparticles Using Stress-Specific Bioluminescent Bacteria*. Small, 2008. **4**(6): p. 746-750.

Author:
Sidra Anwar

Assignment title:
For Premiums wa.me @ +923340686840

Submission title:
MS Manal Thesis

File name:
MS-Manal Thesis.pdf

File size:
2.17M


Page count:
65

Word count:
12961

Character count:
71074

Submission date:
03-Oct-2022 02:15AM (UTC-0500)

Submission ID:
1915226404



We take your privacy very seriously. We do not share your details for marketing purposes with any external companies. Your information may only be shared with our third party partners so that we may offer our service.

[Return to assignment list](#)

DR. RUMEZA HANIF
Associate Professor
Deptt of Healthcare Biotechnology
Atta-ur-Rahman School of Applied
Biosciences (ASAB), NUST Islamabad

Copyright © 1998 – 2022 Turnitin, LLC. All rights reserved.

MS Manal Thesis

ORIGINALITY REPORT

12%
SIMILARITY INDEX

9%
INTERNET SOURCES

8%
PUBLICATIONS

7%
STUDENT PAPERS

PRIMARY SOURCES

1 Submitted to Higher Education Commission Pakistan Student Paper 3%

2 ue-varna.bg Internet Source 1%


3 Submitted to Marian University Student Paper 1%

4 etheses.whiterose.ac.uk Internet Source 1%

5 link.springer.com Internet Source 1%

6 Pritam Kumar Dikshit, Jatin Kumar, Amit K. Das, Soumi Sadhu, Sunita Sharma, Swati Singh, Piyush Kumar Gupta, Beom Soo Kim. "Green Synthesis of Metallic Nanoparticles: Applications and Limitations", Catalysts, 2021 Publication <1%

7 Salem S. Salem, Amr Fouda. "Green Synthesis of Metallic Nanoparticles and Their Prospective Biotechnological Applications: an <1%


DR. ROMEZA HANIF
Associate Professor
Dept. of Healthcare Biotechnology
Allied Health Sciences School of Applied
Nursing & Health Sciences, NUST Islamabad